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1. INTRODUCTION 
1.1 Effects of opiates on whole animals 
1.11 The pharmacology of opiates: analgesia 
For centuries, mankind has known of the medicinal value and 
psychological effects of opium, which is a powder obtained from the 
seed of the poppy plant, Papaver somniferum. The major ingredient of 
opium which is responsible for its pharmacological effects is the alka-
loid morphine. 
Morphine and other opiates produce analgesia (Jaffe & Martin, 
1975); this action is the basis for the extensive clinical use of these 
drugs. The analgesia produced by morphine is selective in that it 
occurs without loss of consciousness and without obtunding other sen-
sory input. There are two aspects to pain: pain as a discriminative 
sensation, and pain as a subjective experience. The subjective experi-
ence of pain encompasses the emotional reactions to the painful 
sensation, which include anxiety, fear and "suffering." Opiates are 
especially effective in relieving this subjective aspect of pain. 
Other pharmacological effects of opiates include respiratory depres-
sion, meiosis, decreased intestinal motility and psychological actions 
such as drowsiness and mental clouding (Jaffe & Martin, 1975). 
Animal models are used to assess morphine-induced analgesia. The 
subjective aspect of pain as "suffering," which is the component of 
pain most amenable to relief by morphine, cannot be measured in animals 
1 
2 
therefore the effect of morphine is tested on the responses of animals 
to stimuli that are considered noxious, such as radiant heat, irri-
tating chemicals or pinching of the skin. One such method in common 
use is the tail-flick test in rodents (D'Amour & Smith, 1941). In this 
procedure the tail of a restrained rat or mouse is placed in a groove, 
and a high intensity lamp is positioned above the groove. The experi-
menter measures the time interval between switching on the lamp and the 
response of the animal to the heat generated by the lamp. This 
response is ~ characteristic twitch of the tail. Opiates increase the 
duration of time before the animal flicks its tail. Although this test 
is useful for evaluating the antinociceptive activity of drugs, 
D'Amour & Smith (1941) make no claims that the results can be extrapo-
lated to predict the analgesic activity of drugs against deep-seated, 
continuous pain such as that involved in carcinoma. 
Other procedures for evaluating the antinociceptive activity of 
opiates include placing a rodent on a hot plate and measuring the time 
before it licks its paws or jumps (hot-plate test), and tests which 
involve placing a clamp on the tail of a rodent and evaluating either 
vocal responses or attempts to bite the clamp. 
1.12 The opiate receptor 
Opiates produce analgesia by binding to receptors on neurons and 
thus altering the activity of those neurons. A receptor is a macromo-
lecular entity on the membrane of a cell that binds a given class of 
structurally similar molecules with high affinity and selectivity; the 
3 
interaction between the molecule and the receptor produces a charac-
teristic response (Goldstein, Aranow & Kalman, 1974). Saturable, high 
affinity binding sites for opiates have been identified in isolated 
neuronal tissue (Pert & Snyder, 1973a; Simon, Hiller & Edelman, 1973; 
Terenius, 1973) and have been localized to homogenate fractions con-
taining synaptic membranes (Pert, Snowman & Snyder, 1974). Although 
direct evidence is lacking that these binding sites are equivalent to 
the opiate receptors, the two share essential features (Hollt & Wuster, 
'J 
197~). For example, the affinity of a series of opiate compounds for 
~ 
binding sites parallels their pharmacological potency in a given 
tissue (central nervous system: Pert & Snyder, 1973b; peripheral 
nervous system: Creese & Snyder, 1975). Also, opiates bind to these 
sites with much higher affinity than do compounds without opiate activ-
ity. Lastly, both binding and receptor activity are stereospecific; 
levo-isomers of opiates are more effective than dextro-isomers of the 
enantiomeric pair. 
Opiate binding sites are unevenly distributed in the brain 
(Hiller, Pearson & Simon, 1973; Kuhar, Pert & Snyder, 1973). Some 
areas, such as_ structures associated with the limbic system, exhibit q 
high amount of binding, whereas others (cerebellum, white matter) have 
little or no binding. 
1.13 Endogenous opioid peptides 
It is intuitively unlikely that high affinity, stereospecific 
binding sites should exist in brain in order to interact with alkaloids 
4 
extracted from the seed of the poppy. A search for endogenous agonists 
for the opiate receptor resulted in the discovery of the enkephalins 
(Hughes, Smith, Kosterlitz, Fotherfill, Morgan & Morris, 1975). The 
enkephalins are two structurally related pentapeptides that differ only 
5 in their carboxy-terminal amino acid: Tyr-Gly-Gly-Phe-Met for Met -
enkephalin and Tyr-Gly-Gly-Phe-Leu for Leu5-enkephalin. Opiate-like 
substances have also been isolated from extracts of pituitary gland. 
One of these substances, S-endorphin, is a 31-amino acid peptide with 
the sequence of Met5-enkephalin at its carboxy terminus (Cox, Goldstein 
& Li, 1976). S-endorphin, administered by the intracerebral route 
(0.5 - 1.0 ~g) to a mouse, has potent antinociceptive activity as 
assessed by the hot-plate and tail-flick methods (Loh, Tseng, Wei & Li, 
1976). In contrast, high doses of Met5-enkephalin (Ec50 = 75 ~g) and 
Leu5-enkephalin (EC50 = 240 ~g) must be administered intracerebro-
ventricularly to produce a short-lasting (2-5 min) antinociception in 
mice (Buscher, Hill, Romer, Cardinaux, Closse, Hauser & Pless, 1976). 
This result can be explained by the rapid enzymatic degradation of 
these peptides. Structural analogs of the enkephalins which are 
resistant to enzymatic degradation have been synthesized. One such 
analog, D-Ala2-Met5-enkephalinamide (DAEA), has potent, long-lasting 
(up to 2 h) antinociceptive activity (tail-flick test) if injected 
(5 or 10 ~g) directly into the periaqueductal region of rat brain 
(Pert, Pert, Chang & Fong, 1976). 
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1.2 Effects of opiates on single neurons 
1.21 In vivo 
Morphine and other opiates alter the firing rate of single 
neurons as measured by extracellular recordings from intact animals. 
Several criteria are used to ascertain if a given alteration in 
neuronal activity induced by application of an opiate drug is mediated 
by interaction with opiate receptors. The effect should occur with low 
concentrations of opiate agonists. The effect should be stereospecific: 
mimicked by (-) isomers but less effectively by (+) isomers of opiate 
agonists, and blocked by (-) isomers but not (+) isomers of opiate 
antagonists. Also, the effect should be prevented or reversed by low 
concentrations of naloxone. The most common stereospecific, naloxone-
reversible effect of opiates is inhibition of neuronal firing 
(Zieglgansberger & Fry, 1978). Such neuronal activity may be sponta-
neous or induced by iontophoretic application of excitatory substances 
such as L-glutamate. The activity of single neurons in the frontal 
regions of the cerebral cortex, the striatum, thalamus, brain stem and 
dorsal horn o~ the spinal cord is inhibited by systemic or ionto-
phoretic application of opiates. Two exceptions to this generaliza-
tion are pyramidal cells of the hippocampus and Renshaw cells of the 
ventral horn of the spinal cord; opiates predominantly excite these 
neurons. The correlation between the sensitivity to opiates of neurons 
in a given brain region and the density of opiate binding sites in that 
same region is good. For example, morphine inhibits the firing of 
neurons in the noradrenergic nucleus locus coeruleus (Korf, Bunney & 
Aghajanian, 1974), an area that has a high density of opiate binding 
sites (Pert, Kuhar & Snyder, 1976). 
6 
North (1979a) discusses the advantages and limitations of extra-
cellular recordings of neuronal activity in vivo. One advantage is 
that neurons are observed in their natural environment with relation-
ships and connections to other cells intact. Also, the cells can be 
anatomically and functionally defined. The methods of applying drugs 
to neurons create difficulties in interpretation of data from extra-
cellular recordings in vivo. Problems of access and metabolism attend 
systemic administration of drugs. A substance applied systemically 
could produce an effect on a given neuron by changing the activity of a 
separate population of neurons which project to the recording site, or 
could alter neuronal activity by an effect on respiration, blood 
pressure or blood flow. Application of a drug by iontophoresis largely 
eliminates these concerns. But results obtained by iontophoretic 
application of drugs should be interpreted with caution because the 
transport number for the drug and the location of the pipette relative 
to the neuron _under study vary. The concentration of drug at the 
neuronal receptor sites is unknown. A substance applied by ionto-
phoresis could be producing an effect either by a direct action on the 
neuron under study, or by presynaptic modulation of synaptic input to 
the neuron. An example of the latter circumstance is the excitation of 
hippocampal pyramidal cells by morphine; this excitation is actually 
due to disinhibition in that morphine is depressing the activity of 
nearby basket cells which tonically inhibit the pyramidal cells 
(Zieglgansberger, Siggins, French & Bloom, 1978). 
7 
Actions of opiates on neuronal activity in vivo can also be 
influenced by the method of preparation of the animal and its physiol-
ogical condition at the time of the recording. Thus morphine is more 
effective in inhibiting firing of dorsal horn cells in the spinal cord 
of animals that are spinalized rather than decerebrate; in decerebrate 
animals the cells are already influenced by a strong descending inhibi-
tion (see North, 1979a). Also, the effect of morphine on the activity 
of neurons in the dorsal raphe area of the periaqueductal gray region 
depends on the presence or absence of general anaesthesia (Urea & 
Liebeskind, 1979). The initial activity level of the neurons as influ-
enced by anaesthesia may determine the presence or direction of an 
effect of morphine on firing rates. There is some evidence that 
opiates are more likely to inhibit a neuron that is firing at a high 
frequency (North, 1979a). 
1.22 In vitro 
Tissues ~ontaining neurons or nerve processes which possess 
opiate receptors can be removed from the animal and maintained in a 
viable condition for long periods of time. The use of such prepara-
tions offers several advantages over the use of in vivo preparations. 
The ionic and chemical environment of the tissue may be controlled and 
drugs can be applied in known concentrations by superfusion. The site 
of action of drugs can be inferred by intracellular recordings from 
single cells or by measurement of transmitter release from nerve 
8 
terminals. The use of anaesthetic drugs is avoided. 
Neurons which are sensitive to opiates can be found in various 
parts of the peripheral nervous system. The myenteric plexus of the 
guinea-pig ileum is a well-studied example. Morphine inhibits the 
activity of the ganglion cells of the myenteric plexus (Satoh, 
Takayanagi & Takagi, 1973; Dingledine & Goldstein, 1976). The activity 
recorded by the extracellular glass suction electrodes arises from 
mechanical irritation of the cells by these electrodes (North & 
Williams, 1977). Enkephalins and S-endorphin also inhibit the firing 
of these cells (North & Williams, 1976; Williams & North, 1979). 
Neurons grown in tissue culture have also been used to study the 
actions of opiates. Several effects of Leu5-enkephalin applied by 
iontophoresis to cultured mouse spinal neurons have been observed 
during intracellular recordings from these cells (Barker, Gruol, Huang, 
Neale & Smith, 1978; Barker, Smith & Neale, 1978). Rapid depolariza-
tions (in 10% of cells) and slow hyperpolarizations (in 33% of cells) 
have been observed upon application of enkephalin to cell somata. Both 
responses are associated with a change in membrane input resistance. 
In other cells_ (12/37 tested), enkephalin directly depresses excit-
ability by elevating the threshold for generation of action potentials 
by intracellular injection of depolarizing current, an action that is 
sometimes antagonized by naloxone (3/6 cells tested). The depression 
of excitability is not associated with changes in resting membrane 
properties in the majority of cells (8/12). A third action of 
enkephalin in these cells is modulation of responses to iontophoretic 
9 
application of amino acids. For example, glutamate-induced depolariza-
tions are either inhibited (28/32 cells) or not affected (4/32 cells) 
by Leu5-enkephalin. The depression of the glutamate response is not 
accompanied by changes in resting membrane properties, and can be par-
tially prevented by co-iontophoresis of naloxone together with 
enkephalin (6/10 cells). 
Caution should be exercised in evaluating the relevance of these 
studies to physiological actions of opiates in vivo. Cultured neurons 
grow in mono~ayers, whereas brain structure is three-dimensional. 
Definite alterations from the usual neuronal organization and physiol-
ogy thus occur. However, such cells are useful for studying drug 
actions on neuronal membrane properties and on monosynaptic trans-
mission. 
Maintenance of slices of brain tissue in vitro is a difficult 
technique that offers promise for elucidating the mechanisms of action 
of opiates on central neurons without the problems associated with in 
situ recording (see above). Intracellular recordings have been made 
from neurons located in the nucleus locus coeruleus of slices of 
guinea-pig pons (Pepper & Henderson, 1979). When these cells are 
superfused with solutions containing normorphine (300 nM- 3 ~M), 
hyperpolarizations associated with a decrease in input membrane resis-
tance are observed (Henderson, personal communication). These hyper-
polarizations may underlie the decrease in activity of these neurons 
when morphine is iontophoretically applied to them in situ (Korf 
~ al., 1974). 
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1.23 Effects of prolonged exposure 
Repeated admin~stration of narcotics leads to the development of 
tolerance to their acute effects. Tolerance is a "state in which 
repetition of the same dose of a drug has progressively less effect, or 
in which the dose needs to be increased to obtain the same degree of 
pharmacological effect as was caused by the original dose" (Isbell & 
Chrusciel, 1970). Repeated exposure to narcotics also produces depen-
dence. Dependence is a state, "resulting from the interaction between 
a living organism and a drug" (Isbell & Chrusciel, 1970), characterized 
by the appearance of an abstinence or withdrawal syndrome when morphine 
administration is discontinued or when the action of morphine is termi-
nated by a narcotic antagonist such as naloxone (Jaffe, 1975). 
1.231 In vivo 
Neurons can be exposed to morphine in vivo for long periods of 
time by treatment of an animal with repeated systemic injections of 
morphine, a single injection of a sustained release formulation of the 
drug ~r by implantation of morphine-containing pellets. After animals 
are chronically treated with morphine, the drug becomes less effective 
in depressing spontaneous or evoked firing of single neurons in 
several brain regions (Satoh, Zieglgansberger & Herz, 1976; Aghajanian, 
1978; Dafny, Brown, Burks & Rigor, 1979). These results may indicate 
that tolerance to the inhibitory action of morphine has developed. 
Another interpretation is that only the activity of morphine-insensi-
tive neurons is recorded because the activity of morphine-sensitive 
11 
cells is suppressed by the continuous presence of the drug in vivo. Or 
the observed tolerance may be a secondary consequence of systemic 
changes in the levels of circulating hormones (Gibson & Pollock, 1975). 
A greater percentage of neurons respond to the iontophoretic 
application of naloxone with an increase in their firing rate in 
morphine-pretreated animals as compared to naive animals (Frederickson, 
Norris & Hewes, 1975; Fry, Zieglgansberger & Herz, 1978). Extra-
cellular recording from single neurons in vivo cannot distinguish 
between at least two mechanisms for this excitatory action of naloxone. 
The neurons could increase their firing rate in response to naloxone as 
a result of altered synaptic input such as the enhanced release of an 
excitatory transmitter or the decreased release of an inhibitory trans-
mitter from nerve terminals. Or the morphine-sensitive neurons them-
selves could become more excitable. In either case, the effect of 
naloxone could be simply a reversal of the depression of neuronal 
activity caused by the continuous presence of morphine, and not a 
manifestation of precipitated withdrawal. One could argue against this 
possibility by demonstrating that the neurons in morphine-pretreated 
animals fire spontaneously at the same frequency as they do in naive 
animals (Aghajanian, 1978). 
1.232 In vitro 
The cellular adaptation which results in tolerance takes place if 
neurons are continuously exposed to opiates in vitro as well as in vivo, 
as has been demonstrated with the opiate-sensitive neurons of the 
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myenteric plexus of the guinea-pig ileum. If tissues are incubated for 
24 h in Krebs solution containing morphine (1 ~M), then the firing rate 
of single neurons usually is not changed by higher concentrations of 
morphine (10 or 30 ~M) (North & Karras, 1978b). The activity of these 
neurons is usually depressed by much lower concentrations of opiates 
(10 nM- 1 ~M normorphine: North & Williams, 1977). The tolerance to 
morphine occurs in these cells even if the tissues are incubated in 
vitro for 24 h with hyoscine and hexamethonium together with morphine; 
these drugs ~nhibit synaptic activity in the myenteric plexus. Thus 
transsynaptic activity is not required for the development of tolerance 
to opiates at the level of the single neuron. 
The addition of naloxone to myenteric neurons which have been 
chronically exposed to morphine in vitro results in a marked increase 
in their firing rate (North & Karras, 1978b). The firing frequencies 
seen under these circumstances are never observed in naive tissues. 
Thus naloxone produces a withdrawal syndrome in these neurons; this 
phenomenon may be characterized by an enhanced excitability of the 
cells. 
1.24 Cellular sites of action 
The action of opiate drugs on single neurons has thus been exam-
ined in both in vivo and in vitro preparations. This work has revealed 
that opiates alter neuronal activity by three mechanisms (see North, 
1979b). First, opiates can have a direct postsynaptic effect on a 
neuron, modifying its membrane properties so as to change its excita-
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bility. A second action, also postsynaptic, is neuromodulation, or 
modification of the response of the neuron to transmitters. This 
latter effect occurs without changes in resting membrane properties; 
inhibition of transmitter-induced activation or inactivation of ionic 
currents could be involved. A third mechanism of action of opiates is 
presynaptic inhibition, or alteration of evoked transmitter release 
from axon terminals. 
A presynaptic location of opiate binding sites in some brain 
regions is suggested by results from binding studies and autoradio~ 
graphy. For example, a significant reduction in the binding of [3H]-
naloxone in the upper dorsal horn of the spinal cord is the result of 
cutting the dorsal roots (Lamotte, Pert & Snyder, 1976). This suggests 
that the binding sites are associated with the primary afferent termi-
nals. The results of deafferentation of the vagus and accessory optic 
systems in the rat also point to a localization of [3H]-diprenorphine 
binding sites to the small diameter unmyelinated sensory fibers of 
these tracts (Atweh, Murrin & Kuhar, 1978). However, the possibility 
that these binding sites are postsynaptic in location and are reduced 
in number by deafferentation because of transsynaptic degeneration 
cannot be dismissed. Definitive localization of opiate binding sites 
to either nerve terminals or nerve cell bodies in brain awaits refine-
ments in anatomical techniques such that autoradiography can be applied 
to electron micrographs of nerve tissue. 
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1.3 Effects of opiates on transmitter release 
Opiates inhibit transmitter release from neurons in several parts 
of the peripheral autonomic nervous system. Two methods are used to 
estimate transmitter release from autonomic nerve terminals (see 
Starke, 1977). One method is to measure the mechanical response of the 
postsynaptic effector cell, the smooth muscle. The general procedure 
is to suspend the tissue in an organ bath through which heated Krebs 
solution is superfused. One end of the tissue is fixed to a rod or 
loop at the bottom of the bath, and the other end is attached to a 
force or a linear-motion transducer. Field stimulation of the intra-
mural nerves is applied by two wire or ring electrodes situated at the 
top and bottom of the bath. The transmitter released from the nerve 
terminals in response to electrical stimuli produces either a change in 
length or a change in tension of the organ. Any change in this mecha-
nical response that occurs upon addition of a drug to the bathing 
medium may reflect a modification of transmitter release, but it may 
also result from postsynaptic effects of the drug. Such effects include 
changes in sensitivity to transmitter, or changes in the efficiency of 
the excitation-contraction coupling process of the muscle. Post-
synaptic effects of a drug are less likely if the drug in question does 
not change the response of the organ to direct application of trans-
mitter substance. 
Another method of measuring nerve-evoked transmitter release is 
to measure the amount of transmitter overflowing into the superfusing 
Krebs solution in response to stimulation of nerves either with elec-
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trical stimulus pulses or with depolarizing solutions of high potassium 
ion concentration. The overflow evoked by such stimuli is distin-
guished from the "spontaneous" overflow. Overflow represents the 
difference between the amount of transmitter released from nerves and 
the amount of transmitter taken back up into cells after its release 
(such reuptake may be neuronal or extraneuronal) . Overflow of trans-
mitter may be estimated chemically or by bioassay. Another technique 
for estimating overflow is to preload the tissue with radiolabelled 
transmitter and to count the radioactivity released into the super-
fusion fluid. It is important to exclude an action of a drug on 
transmitter reuptake before concluding that the drug alters transmitter 
release as estimated by the overflow method. 
1.31 Guinea-pig ileum 
Morphine inhibits the contractile response of the longitudinal 
muscle and also the release of acetylcholine evoked by coaxial stimula-
tion of the guinea-pig ileum with electrical pulses of supramaximal 
strength (Paton, 1957). The action of morphine is localized to neurons 
of the myenteric plexus (see above) because acetylcholine release from 
tissues which contain only longitudinal muscle and the myenteric plexus 
is also sensitive to morphine (Paton & Aboo Zar, 1968). 
These actions of opiates on myenteric plexus-longitudinal muscle 
strips of guinea-pig ileum are stereospecific and prevented or reversed 
by naloxone (see Kosterlitz & Waterfield, 1975). Enkephalins also 
inhibit cholinergic neurotransmission in the guinea-pig ileum (Hughes 
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~ al., 1975b; Waterfield, Smokcum, Hughes, Kosterlitz & Henderson, 
1977). 
1.32 Mouse vas deferens 
A mouse isolated vas deferens which has been stripped of its 
connective tissue sheath consists mainly of smooth muscle cells and the 
axons and nerve terminals which innervate them. The noradrenaline 
which is released from these nerve terminals in response to electrical 
field stimulation is most likely the transmitter which produces the 
contractile response of the muscle (see below). Muscle contractions 
elicited by supramaximal electrical stimulation at a frequency of 0.1 
Hz are inhibited by morphine (70 nM- 2.3 ~M) (Henderson, Hughes & 
Kosterlitz, 1972). The inhibitory effect of morphine and other opiates 
on neurotransmission in this tissue occurs with low concentrations of 
drug, is stereospecific (the (-) isomers but not the (+) isomers of 
opiate agonists are active), and can be prevented or reversed by 
naloxone (Hughes, Kosterlitz & Leslie, 1975). Fulfillment of these 
criteria indicate that this action in the mouse vas deferens is 
mediated by specific opiate receptors similar to those found in brain 
tissue. The relative agonist potencies of a series of opiates in 
causing an inhibition of neuro-effector transmission in the mouse vas 
deferens correlate with the potencies of these same compounds in pro-
ducing analgesia in man (Hughes et al., 1975a). The electrically-
evoked contractions of the muscle are also inhibited by Met5-enkephalin, 
Leu5-enkephalin and S-endorphin (Hughes et al., 1975b; Waterfield 
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et al., 1977). The inhibitory potencies of normorphine (Hughes et al., 
-- --
1975a) and Met 5-enkephalin but not Leu5-enkephalin (Hart, Kitchen & 
Waddell) are increased by reducing the current strength used to elicit 
the muscle contraction. 
The spontaneous overflow of labelled catecholamines (after incu-
bation of the vas deferens in solutions containing either [3H]-tyrosine 
or [3H]-noradrenaline) is not affected by morphine (Hughes et al., 
1975a). Morphine (Henderson et al., 1972) and enkephalin (Waterfield 
et al., 1977) do inhibit the overflow of noradrenaline evoked by elec-
trical stimulation of the intramural nerves. The concentrations of 
opiates which inhibit noradrenaline overflow are similar to the concen-
trations which inhibit the muscle contractions. The effect of opiates 
on transmitter release is dependent on the frequency of nerve stimula-
tion used to evoke the release: morphine (1 ~M) depresses the frac-
tiona! noradrenaline output per pulse at a stimulation frequency of 1.5 
Hz but not at 15Hz (Henderson & Hughes, 1976). 
Opiates and opioid peptides therefore inhibit nerve-evoked muscle 
contractions and transmitter release in the mouse vas deferens. The 
response of the smooth muscle to exogenous noradrenaline is, however, 
not altered by these substances (Henderson & Hughes, 1976). These 
results indicate that the opiate receptors in this tissue are located 
presynaptically on the adrenergic nerves and not postsynaptically on 
the smooth muscle cells. 
The potency of morphine and opioid peptides in inhibiting neuro-
transmission in the vas deferens is dependent on the strain of mouse 
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used for the experiment. For example, morphine (1 ~M) inhibits con-
tractions and noradrenaline release from vasa removed from T.O. mice, 
but not from vasa of C57/BL mice (Henderson & Hughes, 1976). On the 
other hand, Met 5-enkephalin and Leu5-enkephalin are approximately equi-
potent in vasa from both of these strains (Waterfield, Lord, Hughes & 
Kosterlitz, 1978). In a study of seven different strains of mice, 
Szerb & Vohra (1979) found no correlation between sensitivity to nor-
morphine and sensitivity to Met5-enkephalin. The contractions of the 
isolated vas deferens of the rat are not inhibited by either morphine 
or the enkephalins except in very high concentrations. This tissue is, 
however, sensitive to S-endorphin, with an Ec50 of 130 nM for inhibi-
tion of the muscle contractions (Lemaire, Magnan & Regoli, 1978). This 
effect of S-endorphin on the rat vas deferens is reversed by naloxone. 
The differential sensitivities to opiates and opioid peptides of 
vasa from different species and from different strains of the same 
species suggests a heterogeneity of receptor populations. The concept 
of multiple types of opiate receptor originated with Martin and his 
colleagues (Martin, Eades, Thompson, Hupplier & Gilbert, 1976). Based 
on the behavioral and electrophysiological effects of various morphine 
derivatives which they observed in the chronic spinal dog preparation, 
these investigators postulated the existence of three classes of opiate 
receptor. In their scheme, typical morphine-like compounds interact 
with the ~ receptor. Another system of classification of opiate recep-
tors was proposed by Lord, Waterfield, Hughes & Kosterlitz (1977) based 
on the following evidence. First is the comparison of the pharmacolog-
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ical potencies of opiates and opioid peptides in the guinea-pig ileum 
and mouse vas deferens bioassay systems. The mouse vas deferens is 
less sensitive to morphine than is the guinea-pig ileum; the opposite 
is true for the potencies of the enkephalins. S-endorphin is equally 
effective in these two systems. Secondly, measurement of the potency 
of opiates and opioid peptides in inhibiting the binding of labelled 
ligands to homogenates of guinea-pig brain reveals the presence of two 
distinct binding sites. Some opiates are more potent inhibitors of the 
binding of [ 3H]-naloxone whereas others preferentially inhibit the 
binding of [3H]-Leu5-enkephalin. Lord et al. (1977) propose that the 
sites which preferentially bind naloxone and morphine are ~ receptors 
and the sites which preferentially bind Leu5-enkephalin are 8 recep-
tors. In the guinea-pig ileum, enkephalins interact mainly with the~ 
receptor, whereas in the mouse vas deferens they probably interact with 
the putative 8 receptor. To account for the selective sensitivity of 
the rat vas deferens to S-endorphin, a receptor which preferentially 
binds this substance (the E receptor) has been postulated (Wuster, 
Schulz & Herz, 1979). 
The vasa deferentia of mice which are sensitive to enkephalins 
but not morphine (C57/BL strain) presumably possess many 8 receptors 
but few~ receptors. Vasa of mice of the T.O. strain, which are sensi-
tive to normorphine, presumably possess comparatively more functional ~ 
receptors. Apparently the ratio of~- and a-receptors in the mouse vas 
deferens is variable and genetically determined (Waterfield et al., 
1978). Recently specific binding sites for [3H]-Met 5-enkephalin, [3H]-
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dihydromorphine and [3H]-naltrexone have been demonstrated for the 
first time in the vas deferens of the T.O. strain of mouse (Leslie & 
Kosterlitz, 1979). Such binding can only be observed if tissue homo-
genates are incubated with labelled ligand at 0° C, and not at 37° C. 
The affinity of naltrexone for opiate binding sites is lower in the 
mouse vas deferens than in the guinea-pig ileum. Because the opiate 
antagonists naltrexone and naloxone preferentially bind to the ~ recep-
tor and bind less potently to the 8 receptor, this result is compatible 
with the view that the mouse vas deferens has relatively more 8 recep-
tors than the guinea-pig ileum. More accurate quantitation of ~ and 8 
binding sites awaits refinements of experimental technique that will 
improve the ratio of specific to non-specific binding of opiates that 
can be measured in the mouse vas deferens. 
1.33 Other neuro-effector junctions 
Opiates and/or opioid peptides inhibit transmitter release at 
several other autonomic neuro-effector junctions. Examples of such 
systems include adrenergic neurotransmission in the cat nictitating 
membrane (Trenftelenburg, 1957), cholinergic neurotransmission in the 
sinoatrial node-right atrium preparation of the rabbit (Kennedy & West, 
1967) and non-adrenergic inhibitory transmission in the guinea-pig 
taenia coli (Shima & Ishii, 1978). It is not known why opiates inhibit 
neuro-effector transmission in some, but not all, autonomic end-organs 
(see Henderson, Hughes & Kosterlitz, 1978), although a selective 
distribution of opiate receptors is a likely possibility. 
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1.34 Slices of brain 
Opiates can modify the evoked release of putative neurotrans-
mitter substances from brain slices. In slices of rat cerebral cortex 
preincubated with [3H]-noradrenaline, the spontaneous overflow of 
tritium is not altered by morphine. Morphine (100 nM- 10 ~M) did 
decrease the augmentation in the overflow of tritium during electrical 
field stimulation at frequencies of 0.3-3 Hz (Mentel, Starke & Weber, 
1974). Met 5-enkephalin (100 ru~- 10 ~M) had the same effect (Taube, 
Borowski, Endo & Starke, 1976). In these experiments, the depressions 
of stimulus-evoked overflow by morphine and enkephalin were both 
blocked by naloxone. Opioids reduce the release of dopamine from 
striatal slices (Loh, Brase, Sampath-Khanna, Mar, Way & Li, 1976) and 
the release of substance P from the trigeminal nucleus (Jessel & 
Iversen, 1977), ~hilst increasing the release of purines from cortical 
tissue (Fredholm & Vernet, 1978). In these latter three studies, over-
flow of labelled putative transmitter was induced by superfusion with 
high potassium solutions. 
In order to evoke the release of a measurable amount of radio-
labelled substance from brain slices or peripheral neuro-effector 
junctions, high potassium solutions or a high frequency of electrical 
stimulation are usually employed. In the former instance, such concen-
trations of potassium far exceed any that would be encountered physio-
logically in the extracellular fluid. Concerning the latter circum-
stance, morphine is a more effective inhibitor of transmitter release 
at low rather than at high frequencies of nerve stimulation (Henderson 
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& Hughes, 1976). Measurements of overflow of labelled substances are 
thus not the best experiments for evaluating the actions of opiates on 
transmitter release. Transmitter release evoked by single pulse stimu-
lation of nerves is most sensitive to the inhibitory action of opiates. 
1.35 Effects of prolonged exposure 
The nerve-mediated contractions of the isolated myenteric plexus-
longitudinal muscle preparation of the guinea-pig ileum are less sensi-
tive to inhibition by morphine if the tissue is prepared from a 
morphine-pretreated animal (Goldstein & Schulz, 1973; Ward & Takemori, 
1976; Johnson, Westfall, Howard & Fleming, 1978). The degree of toler-
ance, as assessed by the ratio of the Ec50 value for morphine in 
preparations from morphine-pretreated vs. naive animals, ranges from 3 
up to 18-fold. This variation results from differences in experimental 
protocols among investigators, such as the schedule of administration 
of morphine and the time elapsed between removing tissue from the 
animal and testing the degree of tolerance (North & Karras, 1978a). 
Most studies of the induction of tolerance in the guinea-pig ileum 
involve placing the tissue in drug-free Krebs solution after its 
removal from the animal. This procedure results in withdrawal of the 
tissue from the morphine to which it has been continuously exposed in 
vivo. If strips of myenteric plexus-longitudinal muscle from morphine-
pretreated guinea-pigs are maintained in Krebs solution containing 
normorphine and then challenged with naloxone, the muscle exhibits a 
contracture (Schulz & Herz, 1976). This response to naloxone rapidly 
disappears if the tissue is·washed in morphine-free Krebs solution. 
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The contracture results from an action of naloxone on neurons in the 
myenteric plexus and not from a direct action on the smooth muscle be-
cause it is blocked by tetrodotoxin and atropine. 
Tolerance in the guinea-pig ileum is not accompanied by a change 
in the sensitivity of the smooth muscle to acetylcholine (Goldstein & 
Schulz, 1973; Johnson et al., 1978). Therefore tolerance must develop 
to the effects of opiates on the cholinergic neurons of the myenteric 
plexus. Opiates have two actions on these cells: inhibition of their 
firing rate and inhibition of the amount of acetylcholine they release 
(see above). The tolerance to opiates observed with the contractions 
of the muscle may be a consequence of tolerance to either or both-of 
these effects. The release of acetylcholine depends both on the number 
of neurons excited by a given stimulus and on the amount of acetyl-
choline secreted by the nerve terminals of the activated neurons. 
For neurons with opiate receptors on their nerve terminals, t"~vo 
mechanisms can explain the development of tolerance to the action of 
morphine. The nerve terminals themselves may adapt to the continuous 
presence of opiates so that, during withdrawal, transmitter release in 
response to nerve impulses is greatly enhanced as a result of this 
compensation (see Mentel, Starke & Taube, 1975). On the other hand, 
the postsynaptic receptors may become supersensitive, allowing synaptic 
transmission to return to its normal level ("tolerance") in the face of 
a continued depression of transmission by morphine. Upon withdrawal of 
morphine, transmitter release would return to normal, but the post-
synaptic supersensitivity would result in a neuronal abstinence syn-
drome (see Llorens, Martres, Baudry & Schwartz, 1978). 
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1.4 Role of cAMP in the actions of opiates on neurons 
Adenosine 3' ,5 1 -cyclic monophosphoric acid (cAMP) is formed 
from ATP by the membrane-bound enzyme adenylate cyclase. Cyclic AMP is 
believed to be an intracellular "second messenger" that plays a crucial 
role in the recognition and transduction of signals generated by the 
binding of hormones and transmitters to the external surfaces of excit-
able membranes (see Nathanson, 1977). The active substance cAMP is 
hydrolyzed to the inactive 5'-AMP by cAMP-specific phosphodiesterases. 
Three pieces of evidence implicate cAMP in the actions of 
opiates. Firstly, mice that have received injections of cAMP are less 
sensitive to the antinociceptive effect of morphine (Ho, Loh & Way, 
1973). Secondly, opiates inhibit the prostaglandin-stimulated forma-
tion of cAMP in homogenates of rat brain (Collier & Roy, 1974a). 
Finally, opiates inhibit the enzyme adenylate cyclase in neuroblastoma 
x glioma hybrid tumor cells (Sharma, Nirenberg & Klee, 1975). These 
results led to the proposal that the effects of opiates, such as anal-
gesia, are mediated by an inhibition of the adenylate cyclase system in 
opiate-sensitive neurons (Collier & Roy, 1974b). The relationship 
between cAMP and opiates in both in vivo and in vitro svstems has there-
--- " 
fore been extensively studied. 
1.41 Effects of adenosine cyclic nucleotides and phosphodiesterase 
inhibitors on the actions of opiates 
Ho et al. (1973) assessed the effects of cyclic nucleotides on 
the antinociceptive activity of morphine by using the tail-flick test 
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in mice. This group found that the intracerebral administration of 
cAMP (28 ~g/mouse) 1 or 35 h before a test dose of morphine produces a 
significant decrease in the effectiveness of morphine in inhibiting the 
tail-flick response. Furthermore, the intravenous administration of 
cAMP or its dibutyryl derivative, dbcAMP (10 mg/kg), 6 h before the 
morphine injection also lessens the effectiveness of morphine. The 
cyclic nucleotides are effective even if these substances are adminis-
tered 24 h before the tail-flick experiment. 
It is difficult to envision how a small quantity of a rapidly 
degraded substance such as c~~. administered peripherally, can alter 
the action of a drug which acts on centrally located neurons. Morphine 
and cAMP could be acting at two completely different sites, for example 
two anatomically distinct populations of neurons, in altering the 
response of an animal to noxious stimuli. It is impossible to detect 
if intracerebral or intravenous administration of cAMP is elevating 
intracellular levels of cAMP in the neurons involved in the antinoci-
ceptive activity of morphine. The site of action of cAMP could even be 
peripheral, affecting either the afferent (stimulus perception) or the 
efferent (ability of animal to effect movement) limbs of the nocicep-
tive reflex. One substance can also alter the action of another by 
changing the metabolism or distribution of the latter. The effective-
ness of the peripheral administration of cAl~ addresses these 
possibilities. 
An interaction of cAMP and morphine at the level of the single 
neuron has been tested in vivo. Neurons in lamina V of the spinal cord 
(spinalized cats) increase their firing rate in response to noxious 
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cutaneous stimuli (heat) applied to their peripheral fields. The 
activity induced in these cells by noxious stimuli and recorded by 
extracellular electrodes is reduced by iontophoretic application of 
morphine (30-250 nA of current, for 4-35 min) into the substantia 
gelatinosa (Duggan, Hall & Headley, 1977). This effect of morphine is 
not changed by the simultaneous iontophoretic application of both mono-
butyryl cAMP and a phosphodiesterase inhibitor (at currents of 150 nA) 
through the same multi-barrelled pipette (Duggan & Griersmith, 1979). 
By themselves these compounds do not alter the responses of the neurons 
to noxious input if administered into the substantia gelatinosa using 
similar injection currents in other experiments. The administration of 
phosphodiesterase inhibitors in this and in other experiments is in-
tended to increase the intracellular concentrations of cAMP by pre-
venting metabolism of this substance. 
Can pretreatment with cAMP or phosphodiesterase inhibitors block 
the effects of morphine on isolated tissues? The isolated guinea-pig 
ileum myenteric plexus-longitudinal muscle preparation has been used to 
address this question. The action of morphine on this tissue can be 
measured in three ways: inhibition of the nerve-evoked twitch of the 
muscle, inhibition of evoked acetylcholine release and inhibition of 
the firing of single myenteric neurons. If the twitch response of the 
muscle is studied, phosphodiesterase inhibitors interact with morphine 
in various ways. MOrphine is less potent in producing an inhibition of 
the muscle contraction in the presence of the phosphodiesterase 
inhibitor theophylline (500 ~M) (Sawynok & Jhamandas, 1976), although 
other investigators report no effect on the action of morphine of a 
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higher concentration (3 mM) of theophylline (Gintzler & Musacchio, 
1975). Morphine is more effective in the presence of the phospho-
diesterase inhibitors RO 20-1724 (100 ~M) and dipyridamole (10 nM), 
which themselves also inhibit the twitch. But the inhibitions of the 
contractile responses by norepinephrine and adenosine are also enhanced 
in the presence of these compounds. SQ 20,006 (100 ~M), on the other 
hand, has no effect on the action of these inhibitory compounds, or on 
the action of morphine (Gintzler & Musacchio, 1975). Thus not all 
phosphodiesterase inhibitors are active. In these studies an action of 
the phosphodiesterase inhibitor at a postsynaptic site, for example on 
the response of the muscle to transmitter or the efficiency of the 
contractile mechanism, cannot be ruled out. This objection is overcome 
by studying the evoked release of acetylcholine from the myenteric 
plexus. 
Sawynok & Jhamandas (1979) measured the release of acetylcholine 
(by radioenzymatic assay) from longitudinal muscle-myenteric plexus 
strips. Release was evoked by electrical stimulus pulses (36 V, 0.5 
ms) at a frequency of 0.1 Hz, for periods of 10 min. Morphine (300 nM 
and 3 ~M) inhibited this release. The inhibition of release by 
morphine was less in tissues perfused with the methylxanthines theo-
phylline (1 mM), caffeine (3 mM) and 1-methyl-3-isobutylxanthine (IBMX) 
(1 w~) but not in tissues exposed to the non-xanthine phosphodiesterase 
inhibitors RO 20-1724 (10 ~M) or SQ 20,009 (300 ~M). The authors 
attribute the effect of the methylxanthines to an alteration of calcium 
fluxes in the nerve terminal, and not to an elevation of cAMP levels by 
these substances, because elevated calcium ion concentrations and a 
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calcium ionophore also cause an apparent antagonism of the inhibitory 
action of morphine. Several problems with this release study should be 
noted. Some of the phosphodiesterase inhibitors themselves modify the 
release of acetylcholine. Under control conditions, about 20% of the 
measured release is spontaneous (not blocked by tetrodotoxin). If 
these compounds change the ratio of spontaneous to evoked release, they 
could alter the apparent inhibitory action of morphine, as opiates only 
depress evoked transmitter release. Also, two different concentrations 
of morphine (300 nM and 3 ~M) have equal potency in the presence of the 
methylxanthines. Lastly, the results are analyzed by the use of 
multiple t tests instead of by an analysis of variance. This treatment 
would tend to increase the likelihood of the appearance of statistical 
significance. 
A study has been made of the effect of cyclic nucleotides and a 
phosphodiesterase inhibitor on the inhibition by morphine of the firing 
rate of single neurons in the myenteric plexus. In tissues in which 
cAMP levels would be expected to be elevated (by the administration of 
cAMP or dbcAMP, by exposure to prostaglandin E2 and during phospho-
diesterase inhibition by IBMX), the action of morphine on these cells 
was not changed (Karras & North, 1979). This study, which provides the 
most direct measurement in this preparation of the response of a neuron 
to occupation of its opiate receptors by morphine, fails to support the 
hypothesis that the acute action of morphine in altering neuronal 
firing rates is mediated by a decrease in cAMP levels. On the other 
hand, the possibility that the chronic actions of opiates in causing 
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tolerance and dependence could be mediated by a change in the neuronal 
cAMP apparatus was suggested by these authors. 
1.42 The quasi-morphine withdrawal syndrome 
The acute systemic administration of phosphodiesterase inhibitors 
such as theophylline or IBMX results in behaviors that closely resemble 
those seen in morphine-dependent animals that are undergoing withdrawal, 
a "quasi-morphine withdrawal syndrome" (QMWS) (Collier, Francis, 
Henderson & Schneider, 1974; Francis, Roy & Collier, 1975). A subse-
quent injection of naloxone further intensifies these behavioral 
effects of the phosphodiesterase inhibitors (Francis et al., 1975; 
Francis, Cuthbert, Dineen, Schneider & Collier, 1976). Furthermore, 
the administration of methylxanthine phosphodiesterase inhibitors in-
creases the intensity of the symptoms of true naloxone-precipitated 
withdrawal from morphine (Collier & Francis, 1975). Methylxanthines 
have other actions in addition to inhibition of the enzyme that metab-
olizes cAMP (see Sawynok & Jhamandas, 1976 & 1979). But the rank order 
of potency of five phosphodiesterase inhibitors, both xanthines and 
non-xanthines, in producing a QMWS correlates with their potency for 
the inhibition of cAMP phosphodiesterase (Francis, Cuthbert, Saeed, 
Butt & Collier, 1978). The correlation is not perfect, however, as 
papaverine and SQ 20,006 inhibit cAMP phosphodiesterase but do not 
induce QMW (Collier, Butt, Francis, Roy & Schneider, 1976). 
The QMWS is suppressed by opiate drugs (Collier et al., 1974; 
Collier et al., 1976), and their relative potencies in doing so 
correspond to their potencies for eliciting antinociception, for 
binding to sites in brain homogenates and for inhibiting neurally-
evoked contractions of the guinea-pig ileum (Francis et al., 1978). 
But pentobarbitone and haloperidol, which are central nervous system 
(CNS) depressants, also suppress quasi-withdrawal behavior (Francis 
et al., 1978). 
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Collier and his colleagues have pointed out the close similar-
ities between the behavior of animals during true morphine abstinence 
and during quasi-morphine "abstinence" induced by administration of 
phosphodiesterase inhibitors. These investigators postulate that the 
QMWS can be attributed to inhibition of brain phosphodiesterase and 
the consequent increase in cAMP levels in neurons. Therefore they 
conclude that the opiate withdrawal syndrome elicited by the adminis-
tration of naloxone to morphine-dependent animals is associated with an 
increase in levels of cAMP in opiate-sensitive neurons. 
Are there alternative explanations for the behavioral similar-
ities between true morphine abstinence and quasi-morphine "abstinence"? 
If opiate withdrawal involves enhanced excitability of opiate-sensitive 
neurons, as has been suggested by North & Karras (1978a), then any 
compound that ?on-specifically increases the excitability of a similar 
population of neurons would produce a similar pattern of behaviors. 
The cell populations affected by phosphodiesterase inhibitors and 
opiates could overlap but need not be exactly the same, as a given 
behavior can be elicited by more than one neuronal pathway. Naloxone 
would further intensify the excitability of these neurons by removing 
any suppression caused by the presence of endogenous opiates. And any 
CNS depressant, opiate or otherwise, would suppress such a general 
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excitatory phenomenon. Once again a major consideration is the site of 
action - do phosphodiesterase inhibitors limit their actions to the 
pool of neurons that are responsive to opiates? This question can best 
be answered by observations on single neurons or simple neuronal 
systems. 
1.43 Effects of opiates on cAMP metabolism 
The acute or chronic administration of morphine to an animal has 
variable effects on cAMP levels or adenylate cyclase activity measured 
in brain tissue that has been subsequently isolated from the animal 
(Hamprecht, 1978). The interpretation of these in vivo studies is 
difficult as biochemical measurements in the relevant populations of 
morphine-sensitive neurons cannot be made. The majority of activity 
measured is derived from opiate-insensitive neurons or from non-
neuronal brain components such as glia or blood vessels. For example, 
chronic morphine treatment will elevate the activity of protein kinase, 
an enzyme that is regulated by cAMP, even in oligodendroglia (Oguri, 
Lee & Loh, 1976). 
The same_ problem may apply in evaluating the observed alterations 
in cyclic nucleotide levels in brain homogenates or slices that have 
been incubated with opiates. If Collier's hypothesis of the mechanism 
of action of opiates (see above) is correct, then opiates should lower 
cAMP concentrations in these systems. Havemann & Kuschinsky (1978) 
measured cAMP levels in striatal tissue of rats in vitro, in the 
absence and presence of opiates. Slices of striata incubated with 
morphine (500 nM - 50 ~M) accumulate less cAMP than slices incubated 
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without drugs. This effect is not observed in slices incubated with 
both morphine (SO ~M) and naloxone (50 ~M). The decrease in the 
accumulation of cAMP after incubation with morphine (500 nM) (33%) is 
approximately the same as the decrease observed after incubation with 
morphine (SO ~M) (26%). A change in the cAMP concentration in slices 
incubated with opiates could result from drug-induced alterations in 
the activity of either adenylate cyclase or cAMP phosphodiesterase. 
Because incubation with morphine (20-50 ~M) also lowers (by about 20%) 
cAMP levels in cell-free homogenates of striata in the presence of IBMX 
(1 mM), Havemann & Kuschinsky believe the drug is altering cAMP 
synthesis. 
These results in striatal tissues agree with the prediction based 
on Collier's hypothesis, as do the results of other experiments with 
homogenates of rat cortex and hypothalamus (Tsang, Tan, Henry & Lal, 
1978). Other experiments with brain homogenates, slices or mince 
systems have not yielded results in agreement with this prediction (for 
example, Tell, Pasternak & Cuatrecasas, 1975; Katz & Catravas, 1977; 
Tang & Cotzias, 1978). Such discrepancies in results from brain homo-
genates and sl~ces may reflect species or regional differences. But 
more importantly, these biochemical measurements cannot directly relate 
any opiate-induced changes in neuronal activity with changes in cyclic 
nucleotide levels in those same neurons. Morphine may alter cAMP 
levels in brain tissue because of biochemical events subsequent to 
alterations in resting or active membrane properties, or even by a non-
specific action on metabolism. For example, morphine (20 ~M- 2 mM) 
alters cAMP formation in mouse prostate glands in a dose-related manner 
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(Thomas, Dombrowsky, Mawhinney & Sharifi Hossaini, 1975), presumably by 
an action unrelated to neuronal opiate receptors. 
1.44 Experiments with neuroblastoma x glioma cells 
Cells of the neuroblastoma x glioma line NG108-15 exhibit the 
properties of neurons and possess opiate receptors; opiates bind to 
these sites with the same relative affinities as they bind to rat brain 
homogenates (Klee & Nirenberg, 1974). Morphine decreases both basal 
and prostaglandin-elevated cAMP levels in intact hybrid cells and 
inhibits adenylate cyclase activity in cell homogenates (Sharma~ al., 
1975b; Traber, Fischer, Latzin & Hamprecht, 1975). These actions are 
blocked by concurrent incubation with naloxone. Furthermore, long-term 
incubation of these cells in morphine (Sharma, Klee & Nirenberg, 1975), 
enkephalin (Lampert, Nirenberg & Klee, 1976) or endorphin extracted 
from the pituitary (Goldstein, Cox, Klee & Nirenberg, 1977) causes a 
compensatory increase in adenylate cyclase activity which tends to 
overcome the initial inhibition. After this compensation has occurred, 
removal of the opiate produces a large increase in the activity of the 
cAMP system t~ a level greater than before drug incubation. These 
phenomena have been described as the molecular basis for tolerance and 
dependence to opiates (Sharma et al., 1975a). Sodium fluoride, which 
activates basal adenylate cyclase activity and uncouples the enzyme 
from the hormone-receptor complex, abolishes the difference in enzyme 
activities between control cells and cells incubated with morphine. 
Opiates appear to increase the abundance of a high activity form of the 
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enzyme (Sharma, Klee & Nirenberg, 1977). 
The effect of opiates on the biochemistry of the NG108-15 cells 
is not specific, as stimulation of both muscarinic cholinergic (Traber, 
Fischer, Buchen & Hamprecht, 1975) and a-adrenergic (Traber, Reiser, 
Fischer & Hamprecht, 1975) receptors inhibits the activity of adenylate 
cyclase. Long-term incubation of the cells with carbachol or norepi-
nephrine produces a compensatory increase in adenylate cyclase activity 
(Klein, Nathanson & Nirenberg, 1976; Sabol & Nirenberg, 1977), just as 
is seen with incubation in opiates. 
Do the results obtained from the neuroblastoma x glioma hybrid 
cells pertain to the action of opiates in other neuronal systems? The 
NG108-15 cells are tumor cells that differ in unknown ways from dif-
ferentiated neurons. They lack the synaptic connections of neurons in 
their natural environment. The cyclic nucleotide system in these cells 
responds in general to an inhibition of its activity with a compensa-
tory hypertrophy, whether the initial inhibition is produced by an 
opiate, adrenergic or cholinergic agonist (see above). Thus the 
specificity of the response is questionable. Nonetheless, it repre-
sents a biochemical correlate, though not necessarily the specific 
mechanism, of opiate tolerance and dependence in these cells. Some 
form of physiological compensation must be occurring in neurons in 
response to chronic treatment with opiates. The involvement of the 
cyclic nucleotide system in this compensation needs to be studied in 
different types of neurons at central and peripheral sites. 
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1.5 Role of the calcium ion in the actions of opiates on neurons 
The calcium ion is a key regulator of major functions of neurons, 
including cellular metabolism, membrane properties and transmitter 
release. An essential role for the calcium ion as an intermediary of 
the actions of opiates on neurons has been hypothesized (Kaneto, 1971; 
Sanghvi & Gershon, 1977; Ross, 1978). The effects of altered calcium 
ion concentration on actions of opiates and the effects of opiates on 
calcium levels and metabolism in brain tissue form the basis of this 
hypothesis.· 
1.51 The effect of calcium ion on the actions of opiates 
The potency of morphine in producing antinociception is lower in 
mice that have received an injection of calcium ion by the intraventri-
cular route. On the other hand, morphine is more effective in mice 
that have been injected with the calcium chelator EGTA (Kakunaga, 
Kaneto & Hano, 1966; Harris, Loh & Way, 1975). These results have been 
interpreted to suggest that the antinociceptive action of morphine is 
mediated by a decrease in the availability of calcium at some neuronal 
site, and that this deficiency can be overcome by administering high 
doses of calcium. 
Are there alternative explanations for the apparent antagonism by 
calcium of the antinociceptive activity of morphine? Calcium adminis-
tered into the ventricular system of the brain produces sleep and 
anaesthesia in some species; these behavioral effects could mask the 
action of morphine (see Kaneto, 1971). Also, a physiological antagon-
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ism of the action of morphine by calcium may occur at the same or dif-
ferent anatomical sites. Increased concentrations of extracellular 
calcium ion have two important actions on neuronal activity: stabili-
zation of the membrane (Koketsu, 1969) and enhancement of transmitter 
release (Rubin, 1970). Either or both could antagonize the neuronal 
actions of morphine without involvement of a calcium link in those 
actions. 
In in vitro preparations containing neurons that bear opiate 
receptors, opiates can inhibit nerve-evoked muscle contractions, 
depress transmitter release or alter the electrophysiological proper-
ties of neurons. The isolated guinea-pig ileum is an example of a 
tissue in which all three of these actions of opiates are readily 
demonstrable. The effect of changing the external concentration of 
calcium ion on each of these actions of opiates has been tested. In 
these experiments, a decrease in the effectiveness of morphine in 
tissues superfused with solutions containing increased concentrations 
of calcium ion is interpreted to mean that calcium is antagonizing the 
effect of morphine. 
The inhibition by morphine of nerve-mediated muscle contractions 
of the guinea-pig ileum is reduced in tissues maintained in calcium 
(5 roM) compared to tissues maintained in calcium (2 roM) (Heimans, 1975). 
Opmeer & Van Ree (1979) also observed a lowered effectiveness of mor-
phine in guinea-pig ilea maintained in high calcium (5.08 roM) rather 
than normal calcium (2.54 roM) solutions. In these experiments calcium 
may be altering the response of the muscle by increasing the efficiency 
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of excitation-contraction coupling. The measurement of evoked trans-
mitter release in solutions of varying calcium ion concentration 
eliminates problems associated with direct actions of calcium on 
muscle. In a preliminary study, Nutt (1968) observed no change in out-
put from strips of guinea-pig intestine maintained in calcium ion 
concentrations varying over a 10-fold range. But Sawynok & Jharnandas 
(1979) do see a lesser degree of inhibition by morphine of evoked 
acetylcholine release from strips of longitudinal muscle-myenteric 
plexus if the latter are superfused with three times the normal calcium 
ion concentration. A similar effect occurs in solutions containing the 
calcium ionophore A23187. A puzzling aspect of this report is that the 
amount of transmitter released in response to nerve stimulation was the 
same in high (7.5 mM) calcium as in normal (2.5 mM) calcium. Such a 
large increase in calcium would be expected to enhance stimulus-
secretion coupling. 
Opiates still inhibit the firing of single myenteric neurons in 
solutions that contain no added calcium ion (Dingledine & Goldstein, 
1976; Williams & North, 1979), arguing against an essential role for 
the divalent cation in this action of opiates. Thus even in the same 
tissue the effect of calcium differs, depending on how the action of 
opiates is measured. The myenteric plexus is a complex neuronal 
assembly in which the release of acetylcholine from the autonomic 
neurons innervating the longitudinal smooth muscle could be influenced 
in many ways and controlled at multiple sites. A more desirable system 
for the study of the calcium-opiate interaction is a simple preparation 
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in which actions of calcium at loci other than on the neurons with 
opiate receptors can be minimized or discounted. 
1.52 The effect of calcium ion on the binding of opiates 
Calcium ion could antagonize the actions of opiates in both in 
vivo and in vitro experiments by inhibiting the binding of opiates to 
neuronal receptors. The stereospecific binding of both [3H]-dihydro-
morphine (DHM) and [3H]-naloxone to brain homogenates is significantly 
less in solutions containing calcium ion than in solutions containing 
zero calcium (Pert & Snyder, 1973b; Hitzemann, Hitzemann & Loh, 1974). 
But the stereospecific binding of [3H]-DHM decreases by no more than 
20% with a twenty-fold increase in the calcium ion concentration (1 to 
20 mM); in the physiologically relevant range of calcium ion concen-
trations (1-5 mM), the amount of [3H]-DHM bound varies by no more than 
10% (Pert & Snyder, 1974). Thus the binding of opiates to neuronal 
membranes does not appear to be a major locus of interaction with the 
calcium ion. 
1.53 Effects of opiates on calcium levels and fluxes 
The calcium content of whole brain is reduced in mice that have 
received a large subcutaneous dose of morphine (100 mg/kg but not 20 
mg/kg) (Shikimi, Kaneto & Hano, 1967). The same effect occurs in rats 
that have been injected with morphine (25 mg/kg) (Yamamoto, Harris, 
Loh & Way, 1978), although antinociception can be produced in these 
animals by much lower concentrations of morphine. The effect of 
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morphine administration on calcium levels in brain is dose-related, 
stereospecific and reversed by naloxone (Cardenas & Ross, 1975). The 
calcium loss is localized to synaptosomal fractions (Cardenas & Ross, 
1976; Harris, Yamamoto, Loh & Way, 1977). Animals that have received 
prolonged morphine treatment (by pellet implantation) have higher 
calcium levels in the synaptosomal fractions of their brains (Yamamoto 
~ al., 1978) and an increase in the amount of radioactive label found 
in isolated nerve ending fractions after the in vivo administration of 
labelled calcium ion (Harris et al., 1977). These investigators 
believe that the nerve endings compensate for an initial depletion of 
calcium caused by the acute administration of opiates. This compensa-
tion takes the form of an increase in the content of calcium at these 
sites. 
Several problems are associated with this interpretation of these 
results. Firstly, morphine is not the only centrally active drug 
which, when administered to animals, alters brain calcium levels. 
Ethanol and reserpine also cause an apparent depletion of brain calcium, 
although pentobarbital does not (Ross, Medina & Cardenas, 1974); 
Calcium levels in guinea-pig brain stem are also altered during either 
the excitation or the sleep produced by central stimulants or depress-
ants respectively. General alterations in brain functional activity 
thus can change the distribution and content of calcium in the brain 
(see Kaneto, 1971). Secondly, acute administration of morphine (intra-
peritoneal injection of 6-100 mg/kg) decreases calcium levels to an 
equal extent in eight different brain regions (Cardenas & Ross, 1975). 
There is no correlation between the density of opiate binding sites and 
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the extent of depletion of calcium in a given region. Mice that have 
received morphine have an equal decrease in the calcium content of the 
striatum, an area rich in binding sites, as in the cerebellum, an area 
practically devoid of opiate binding sites (Kuhar et al., 1973). The 
in vivo administration of morphine thus lowers calcium levels even in 
neurons that do not bear opiate receptors. One may argue that the 
calcium effect observed in vivo is likely to be the result of a general 
change in the functional state of the brain which has been elicited by 
the administration of morphine. This is the idea proposed by Kaneto 
(1971) . One possible mechanism is related to the respiratory depres-
sion caused by morphine. Morphine in vivo increases the pco2 , causing 
a decrease in the pH of the brain. An increase in the extracellular 
concentration of hydrogen ions can decrease the calcium content of 
nerve (Baker & Honerjager, 1978). 
Anionic groups of the proteins and phospholipids of cell mem-
branes attract and bind cations such as calcium. Narcotics inhibit the 
binding of calcium to phospholipids in vitro, but high concentrations 
(600 ~M) are required and other centrally active drugs share this 
action. The e.ffectiveness of a given drug correlates with its degree 
of ionization (Mule, 1969). Isolated synaptic membranes prepared from 
whole rat brain minus cerebellum bind radiolabelled calcium ions 
C45ca++) with high affinity CKU = 840 nM). Low concentrations of 
levorphanol (0.5-10 nM) added to the incubation mixture non-competi-
tively inhibit this binding, an effect that is stereospecific and 
blocked by naloxone (10 nM) (Ross & Cardenas, 1977). Both the initial 
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rate and the maximal level of uptake of 45ca++ into homogenates of 
whole mouse brain are lower if morphine or levorphanol (but not dex-
trorphan) are added to the incubation mixture or if the homogenates are 
prepared from mice pretreated with a single injection of morphine 
(10 mg/kg). In homogenates prepared from animals that have been chron-
ically exposed to morphine (pellet implantation), the time required for 
maximal uptake of calcium is shortened, whereas the maximum level of 
uptake is not changed (Guerrero-Munoz, Guerrero & Way, 1978). This 
study does not distinguish between calcium uptake (energy dependent) 
and binding (no requirement for metabolic energy) and the relative 
effect of morphine on each. Therefore similar experiments using lysed 
synaptosomes measured 45ca++ uptake in the presence and absence of ATP 
(Guerrero-Munoz, Guerrero & Way, 1979). Incubation in morphine de-
creases uptake only in the presence of ATP; this suggests that morphine 
inhibits active uptake of calcium by synaptosomes. The postulated 
inhibition by morphine of calcium uptake into a resting nerve terminal 
may not be relevant to any actions of morphine in inhibiting stimulus-
evoked transmitter release. It is consequently of interest that 
incubation witp levorphanol (100 nM) also reduces calcium uptake in 
synaptosomes that have been depolarized by a solution containing high 
potassium (50 mM) (Ross, 1978). 
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1.6 Neuro-effector transmission in the mouse vas deferens 
1. 61 Anatomy 
The smooth muscle of the mouse vas deferens is innervated by the 
sympathetic branch of the autonomic nervous system via the hypogastric 
nerve. Preganglionic sympathetic fibers in the hypogastric nerve 
synapse in ganglia located close to the vas deferens: this organ is 
thus innervated by short adrenergic neurons (Sjostrand, 1965). Like 
most hollow ?rgans, the vas deferens consists of inner circular and 
outer longitudinal layers of smooth muscle. The following description 
of the fine structure of the muscle cells and their innervation in the 
vas deferens of the mouse is a composite of the work of Lane & Rhodin 
(1964) and Jones & Spriggs (1975b). Individual muscle cells are long 
(100-300 ~m) and thin (diameter less than 10 ~m) and are arranged in 
branching and anastomosing bundles. Adjacent cells often appear to 
interlock by "peg and socket" structures - an evagination of one cell 
fits into an invagination of the next. Tight junctions ("nexuses" -
apposing membranes fused) , which are low resistance pathways for flow 
of electrical current between cells, are infrequently found in the 
mouse vas deferens (Yamauchi & Burnstock, 1969). Thus although 
electrophysiological studies reveal electrotonic coupling among the 
cells (see below), the structures which allow such coupling have not 
yet been identified. 
The fine unmyelinated sympathetic fibers run for long distances 
through the smooth muscle before terminating. Large bundles of axons 
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(about 8 axons/bundle) enclosed in Schwann cell sheaths run between the 
muscle bundles. Smaller bundles of axons, sometimes with an incomplete 
sheath, are seen between individual muscle cells. Axons which are 
devoid of a Schwann cell sheath eventually emerge from these bundles 
and run singly between cells; these axons often lie in an indentation 
of a cell or are completely enclosed within smooth muscle cytoplasm 
(Furness & Iwayama, 1971). The single axons are varicose, with alter-
nate constrictions and dilatations of their diameter at regular inter-
vals. The dilated areas, or nodes, contain numerous synaptic vesicles 
and some mitochondria and are presumed to be the sites of transmitter 
release. Nerve varicosities often closely approach the muscle cells; 
neuromuscular clefts of 7-8 nm are common. All cells appear to be 
innervated by one or more such close contacts; this is not the case for 
all smooth muscle organs (see Burnstock, 1970). No postsynaptic 
specializations of the muscle cells are evident. 
Three types of synaptic vesicles are seen within the axonal 
varicosities. Small dense-core (granular) vesicles are much more 
numerous than small electron-lucent (agranular) vesicles: approxi-
mately 73% of axons contain small granular vesicles only, 22% both 
agranular and granular vesicles, and 5% agranular vesicles only. A 
proportion of the axon profiles also contain one or a few large 
granular vesicles. Small granular vesicles are believed to be associa-
ted with the storage of noradrenaline, whereas agranular vesicles are 
identical to those seen at the skeletal neuromuscular junction and are 
presumed to be cholinergic. The contents of large granular vesicles 
are unknown (Burnstock, 1970). 
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Anatomical studies implicate noradrenaline as the transmitter of 
the mouse vas deferens. The noradrenaline content of the tissue is 
high (about 5 ~g/g of tissue) (Sjostrand, 1965). The vas exhibits a 
dense catecholamine fluorescence which is reduced or abolished by pre-
treatment of the mouse with 6-hydroxydopamine (Furness, Campbell, 
Gillard, Malmfors, Cobb & Burnstock, 1970), a toxin which is taken up 
into noradrenergic nerve terminals, displaces noradrenaline from the 
vesicles and subsequently causes degeneration of the nerve terminal 
(Thoenen & Tranzer, 1968). The majority of axons in the mouse vas 
deferens contain small granular vesicles which are the predominant type 
in mammalian sympathetic nerves. The dense core of these vesicles is 
best observed by permanganate fixation of the tissue (Furness et al., 
1970) or by pretreatment of the animal with 5-hydroxydopamine (Chiba, 
1973). The latter substance is a marker for adrenergic nerve terminals 
(Tranzer & Thoenen, 1967). A small number (7-8%) of axons found in the 
mouse vas deferens may be cholinergic (Jones & Spriggs, 197Sa). These 
axons contain small agranular vesicles and acetylcholinesterase 
reaction product on their surface membrane. 
1.62 Mechanical responses 
Some investigators have expressed doubt that noradrenaline is the 
neurotransmitter of the vas deferens (guinea-pig: Ambache & Aboo Zar, 
1971; mouse: Jenkins, Marshall & Nasmyth, 1977). The basis of the 
argument against noradrenaline as the transmitter is three-fold. 
First, the muscle is insensitive to exogenous noradrenaline. Muscle 
contractions evoked by adding noradrenaline to the organ bath rarely 
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compare in amplitude to those evoked by stimulation of the intramural 
nerves. Secondly, the nerve-mediated twitch response of the muscle is 
reduced by exogenous noradrenaline. And, finally, neurotransmission is 
insensitive to blockade by classical a-adrenoceptor antagonists, espe-
cially phenoxybenzamine. Each of these results can be explained with-
out abandoning the noradrenaline hypothesis. The insensitivity to 
exogenous noradrenaline could result from the close packing of the 
muscle cells. The effect of noradrenaline on the smooth muscle peaks 
within 30 s, yet in this time the noradrenaline would diffuse into only 
about 15% of the extracellular space (Jones & Spriggs, 1975b). Trans-
mural stimulation of the nerves effectively activates all of the smooth 
muscle cells. Also, extra-junctional rather than junctional regions of 
the postsynaptic cells would be more accessible to exogenous sub-
stances. By analogy with skeletal muscle, junctional regions in the 
vas deferens may be more sensitive to transmitter. Low concentrations 
of exogenous noradrenaline inhibit the nerve-mediated twitch response 
of the muscle by an action on nerve terminals. Sympathetic nerves 
possess presynaptic a-adrenergic receptors: a-adrenergic agonists 
inhibit and a-adrenergic antagonists potentiate the nerve-evoked re-
lease of noradrenaline (see Starke, 1977). In the mouse vas deferens, 
noradrenaline is less potent in this action than clonidine, but the 
action of both is blocked by yohimbine (Marshall, Nasmyth, Nicholl & 
Shepperson, 1978). Yohimbine is an a-adrenergic antagonist that in low 
concentrations selectively blocks presynaptic receptors. Furness 
(1974) explains that the ineffectiveness of the a-adrenergic antagonist 
phenoxybenzamine in blocking the nerve-mediated twitch may be the 
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result of the closeness of the neuromuscular contacts and the non-
specificity of the drug. Thus the highly charged phenoxybenzamine 
molecule may have difficulty penetrating to the actual site of neuro-
transmission, which in the mouse vas deferens is well insulated (see 
above). Also, phenoxybenzamine has other actions besides postsynaptic 
a-adrenergic receptor blockade, such as antagonism of noradrenaline 
uptake, inhibition of the enzymatic breakdown of noradrenaline and 
potentiation of noradrenaline release by blocking the inhibitory pre-
synaptic a-adrenergic receptors. These four latter actions would tend 
to increase rather than decrease the efficacy of adrenergic trans-
mission. Furthermore, high concentrations of another a-adrenergic 
antagonist, phentolamine-- 53 ~M: Jones & Spriggs (1975b); 360 ~M: 
Henderson (1974) -- do abolish the responses of the vas to both trans-
mural nerve stimulation and exogenous noradrenaline. 
Other findings from organ bath physiology experiments further 
implicate noradrenaline as the transmitter. The mouse vas deferens 
takes up and stores labelled noradrenaline, and the amount of label 
released upon nerve stimulation depends on the stimulation frequency 
and is related to the contractile response of the muscle (Farnebo & 
Malmfors, 1971). Muscle responses to transmural stimulation are 
inhibited by guanethidine (Jones & Spriggs, 1975b) and abolished by 
bretylium but then restored by amphetamine (Henderson, 1974). Also, no 
nerve-mediated contractions can be elicited in vasa from mice pre-
treated with 6-hydroxydopamine (Jones & Spriggs, 1975b). These are 
typical pharmacological responses of an adrenergically innervated organ. 
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1.63 Electrophysiology 
Passive and active membrane responses of smooth muscle can be 
observed by intracellular recordings from individual cells. Junction 
potentials, short-lived changes in membrane potential in response to 
interaction of transmitter with receptors on the smooth muscle mem-
brane, were first described for the vas deferens of the guinea-pig by 
Burnstock & Holman (1961) and for the vas deferens of the mouse by 
Holman (1967). The junction potentials of the vas deferens are depol-
arizing and can be elicited by either stimulation of the hypogastric 
nerve or by field stimulation of intramural nerves. The excitatory 
junction potentials (e.j.ps) of the mouse vas deferens can be evoked by 
both orthodromic and antidromic activation of the intramural nerves, 
indicating that transmitter is released from the varicosities along 
the length of the axon, and not just from axon terminals (Furness, 
1970). The time to peak (rise time) of the e.j.p. is 10-20 ms, and the 
duration is 100-250 ms. The amplitude of the evoked e.j.p. is graded 
with stimulus strength. Increasing the stimulus strength recruits more 
nerve fibers; up to 15-22 fibers may contribute to the e.j.p. in a 
given cell (Furness, 1970). Holman (1967 & 1970) observed that spon-
taneous junction potentials occur with a variable frequency in the 
mouse vas deferens. Their amplitudes range from just above the noise 
level of the recording system (about 1 mV) to about 20 mV. These 
potentials are presumed to result from the spontaneous release of 
transmitter from the adrenergic nerve varicosities because they persist 
in the presence of tetrodotoxin (Hashimoto, Holman & McLean, 1967). 
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The variation in amplitude may be a consequence of transmitter release 
at different distances from the impaled cell, into synaptic clefts of 
differing geometry. The actual amount of transmitter released may 
also vary. 
E.j.ps of smooth muscle have been compared to end plate poten-
tials (e.p.ps) of skeletal muscle. E.j.ps are assumed to result from 
an increase in conductance of the smooth muscle membrane to one or more 
ions, just as the e.p.p. is the consequence of current flowing due to 
an increased conductance of the skeletal muscle fiber membrane to 
sodium and potassium ions (Takeuchi & Takeuchi, 1960). Experiments 
attempting to define the mode of action of noradrenaline on the post-
synaptic membrane are difficult because of the syncytial nature of 
smooth muscle. Smooth muscle cells are, to a greater or lesser extent, 
electrotonically coupled to one another. Caution is warranted in 
interpreting data obtained by intracellular recording from one point in 
a syncytium (Tomita, 1970; Holman & Nield, 1979). The current applied 
at one point, for example from a microelectrode placed in a single 
smooth muscle cell, spreads in three dimensions. The current density 
decreases rapidly with distance from the current source, as the current 
is shunted through the low electrical resistance of the surrounding 
membrane. The area of membrane increases as approximately the cube of 
the distance from the point of current application. Only a small 
amount of the current passes across the membrane of the impaled cell. 
Thus attempts to demonstrate an increased conductance of the smooth 
muscle membrane during an e.j.p. have been unsuccessful because the 
e.j.p. recorded in a given cell is largely or entirely the result of 
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electrotonic spread of depolarization from neighboring cells (Holman, 
1970). Similarly, the amplitude of the e.j.p. in a given cell is not 
altered by changing the membrane potential of that same cell by intra-
cellular injection of current (Holman, 1967). If, however, the entire 
smooth muscle membrane is depolarized with exogenous noradrenaline 
(Furness, 1970) or potassium sulphate (Holman, 1970), the amplitude of 
the e.j.p. is reduced. Interpretation of data obtained in this manner 
is difficult because these treatments alter the properties of the pre-
synaptic nerve terminals as well as the postsynaptic muscle membrane. 
If the smooth muscle membrane is depolarized to + 20 mV by a combin-
ation of potassium sulphate and intracellular current injection, the 
polarity of spontaneous potentials is reversed (Holman, 1970). This 
result may indicate that noradrenaline is increasing the permeability 
of the membrane to sodium and at least one other ion. 
E.j.ps of smooth muscle have also been compared to e.p.ps of 
skeletal muscle in terms of the quantal nature of transmitter release. 
The e.p.p. results from the simultaneous release from the motor nerve 
terminal of many packets (quanta) of transmitter of approximately the 
same size (del Castillo & Katz, 1954). Transmitter release from 
autonomic nerves is also assumed to be quantal, but direct proof is 
lacking. Blakeley & Cunnane (1979) provide some evidence for packeted 
release of transmitter in the guinea-pig vas deferens. They found that 
the evoked e.j.p. has intermittent peaks in its rate of rise which are 
superimposed on a regular, non-intermittent component of the voltage 
change. In some cells, these peaks or "discrete events" have preferred 
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amplitudes which are whole number multiples of their smallest ampli-
tude. Furthermore, a few cells demonstrate spontaneous e.j.ps that are 
of the same amplitude and time course as a discrete event recorded in 
that same cell. The spontaneous potential and the discrete event are 
assumed to result from the release of a packet of transmitter from the 
same varicosity. Thus the rising phase of the e.j.p. has two compo-
nents: discrete events which represent the packeted release of trans-
mitter directly onto the impaled cell, and a slow non-intermittent 
component which represents the electrotonic spread of depolarization 
from neighboring cells. 
1.64 Effects of opiates 
Intracellular recording of an e.j.p. is a sensitive method of 
assaying the small amount of transmitter released from the noradren-
ergic nerve varicosities in response to a single stimulus to the intra-
mural nerves. The inhibition of evoked transmitter release in the 
mouse vas deferens by opiates is reflected in the depression of e.j.p. 
amplitude by normorphine (Henderson & North, 1976). Normorphine does 
not prevent th~ depolarization of the smooth muscle cells by added 
noradrenaline, thus confirming the presynaptic location of the opiate 
receptors. 
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1.7 Research objectives 
The object of this study is to examine the depression by opiates 
of the amplitude of the evoked e.j.p. in the mouse isolated vas 
deferens. The study will investigate factors that modify the opiate-
induced depression of e.j.p. amplitude and hence will try to clarify 
the mechanism by which opiates decrease transmitter release by their 
action on nerve terminals. The specific aims are: 
(1) to study the changes that occur in neuro-effector transmission 
in the mouse vas deferens after chronic exposure to morphine. 
(2) to examine the role of cyclic nucleotides and the calcium ion in 
the acute depressant action of opiates on transmitter release in 
the mouse vas deferens. 
2. METHODS 
2.1 Preparation of the tissue 
Male mice (25-40 g) of the CF-1 strain (ARS, Madison, WI) were 
killed by a blow to the head. Both vasa deferentia were dissected 
free from the pelvic cavity and placed in a Petri dish filled with 
Krebs solution. Vasa are closely invested with a fine connective 
tissue sheath containing the nerve and blood supply to the organ. 
The portion of the sheath containing the main artery was removed. Both 
ends of the tissue were tied with fine silk thread (6-0) in order to 
pull them through ring-shaped stimulating electrodes (see below). 
The tissue was transferred to a bath constructed of perspex. 
This bath had a long rectangular channel filled with a silicone rubber 
resin (Sylgaard, Dow Corning). The bath was secured to the stage of a 
dissection microscope with modeling clay. The vas deferens was placed 
at right angles to the length of the Sylgaard-filled trough and the 
central portion was pinned. A section of the vas was first secured by 
four large pins arranged in the form of a square or rectangle (2 mm x 
2-3 mm); the ~issue was stretched by this procedure so that it pre-
sented a flat surface as opposed to the rounded contour of unpinned 
tissue. The close investment of fine connective tissue of the pre-
senting surface was removed with the aid of fine jeweler's forceps. 
Small pins cut from tungsten wire were used to further stretch and 
immobilize the portion of the tissue delineated by the four larger 
pins. 
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Platinum ring electrodes with an inner diameter approximating the 
diameter of the vas deferens were placed on either side of the tissue. 
Each end of the vas was threaded through a ring electrode, and the 
electrode positioned about 2-3 mm above, and slightly to the side of, 
the pinned out portion of tissue. A wick of tissue paper kept moist 
that portion of the muscle which led to the electrode. 
The tissue was superfused with Krebs solution of the following 
composition (mM): NaCl 118, KCl 4.75, KH2Po4 0.93, CaC12 2.54, 
MgC1 2 ·7H2o 1."19, glucose 11 and NaHC03 25. This solution was continu-
ously gassed with 95% o2 and 5% co2 in its main reservoir. It then 
was pumped at a constant flow rate of 1.5 ml/min through a series of 
three-way taps, through the tubing of a Gilson pump and finally through 
fine polyethylene tubing. The latter tubing was, before leading to the 
tissue bath, invested with a jacket containing heated water. The tem-
perature of the Krebs solution at the site of recording was 35-37° C. 
Drugs or solutions of varying ionic composition were applied to 
the tissue by superfusion. Each drug or solution was contained in a 
separate reservoir and attached to one of the three-way taps. Turning 
the tap changed the Krebs solution from the standard solution to 
another which differed only in its content of drug or in its ionic 
composition. The "dead time" or the time interval between the turning 
of a tap and the appearance of the new solution at the tissue varied 
from 40 s to 1.5 min (depending on tap location, tubing lengths and 
pump speed). 
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2.2 Electrical recording 
Glass capillary tubing (1.0 or 1.2 mm outside diameter), pulled 
to a fine tip by a micropipette puller of the horizontal type 
(Industrial Science, model Ml), was used for recording from single 
smooth muscle cells. The microelectrode was filled with 2M KCl and 
attached to a Narishige micromanipulator. A fine chloridized silver 
wire was inserted into the filled microelectrode. The electrical sig-
nal from the silver wire electrode was magnified lOOX by the pre-ampli-
fier (Nihon-Xohden model MZ-3B) and displayed on two oscilloscopes 
(Tektronix 502A and 535A). The amplifiers on the oscilloscopes were 
DC-coupled. The trace on the 502A oscilloscope was photographed with a 
Grass kymograph camera (model C4R) on 35 mm Tri-X Pan film (Eastman-
Kodak). The second oscilloscope was used for visual observation. 
The resistance of the microelectrode was measured by means of a 
Wheatstone bridge circuit (Figure 1) as described by Araki & Otani 
(1955). The bridge was balanced, that is, the points C and D were iso-
potential, if the current flow was equal through each of the parallel 
arms ~CB and ADB. This occurred if R1/R2 = R3/R4 . The bridge was 
calibrated by substituting known resistances for R2 and adjusting R4 
until no current flowed between points C and D (current trace was mon-
itored on the oscilloscope). The resistance of a given microelectrode 
could be measured by dialing to the resistance (R4) which balanced the 
bridge. Electrodes of resistance 50-80 MQ were most useful for 
stable recordings. 
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Figure 1. Diagram of Wheatstone bridge circuit. The resistances of 
microelectrodes for intracellular recording were measured using the 
Wheatstone, bridge circuit illustrated. R1 was a 1,000 Mn current 
limiting resistor. The resistance of the microelectrode (R2) was 
another arm of the bridge: This arm also contained the lead which 
grounded the tissue bath. The rest of the bridge consisted of a 
10,000 n variable resistor which remained fixed at a given value 
(R3), and a 1,000 n variable resistor which was adjustable (R4). A 
test voltage was ~pplied across points A and B of the circuit. A 
signal related to the potential difference between points C and D was 
amplified and monitored on an oscilloscope. 
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2.3 Impalement of the smooth muscle cells 
The microelectrode was lowered until it just touched the surface 
of the most superficial layer of smooth muscle. This position was 
indicated by a sudden unbalancing of the bridge as the electrode tip 
encountered the resistance of the tissue. The microelectrode was 
driven through the tissue by a succession of advancements by the micro-
manipulator, interspersed with gentle tapping of the micromanipulator 
or table. Cells were impaled by either a gentle tap or by a short 
duration, sudden increase of the amplifier's capacity compensation. 
Successful impalement was indicated by a drop in the DC potential of 
60 mV or greater. 
The resting membrane potentials of cells were measured by sudden 
withdrawal of the recording electrode into the perfusing solution. 
Measurements were made only for cells which showed stable resting 
membrane potentials for longer than 10 min. 
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2.4 Stimulation of the intramural nerves 
The intramural nerves were stimulated by the platinum ring 
electrodes with single rectangular pulses (500 ~s or 1 ms in duration); 
these pulses were generated by a Grass stimulator (model S88) and were 
isolated from ground. The preparation was stimulated at 30 s intervals 
because facilitation of e.j.p. amplitude is not evident at this fre-
quency (Henderson & North, 1976). The stimulus voltage was adjusted so 
that the unfacilitated e.j.p. was between 10 and 25 mV (usually about 
15 mV) in amplitude before measuring the effect of a drug that de-
pressed the e.j.p. These e.j.p. amplitudes were chosen because at 
lower amplitudes the depressant action of a drug is less accurately 
measured and at higher amplitudes non-linear summation (Martin, 1955) 
may become important. The initial e.j.p. amplitude was between 4 and 
12 mV before addition of a drug which increased e.j.p. amplitude. 
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2.5 Prolonged exposure to normorphine in vitro 
After removing the vas deferens from the animal, the tiss~es 
were superfused with Krebs solution containing normorphine (300 nM). 
After 1-5 h of this treatment, the effect of normorphine (1 and 3 ~M) 
on e.j.p. amplitude was tested. The effect of naloxone (300 nM) on 
the e.j .p. was tested after 5-8 h of superfusion with normorphine 
(300 nM). 
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2.6 Prolonged exposure to morphine in vivo 
Vasa deferentia from some mice were exposed to morphine in vivo; 
these mice were given 9 intraperitoneal injections of morphine sulphate 
(doses of 40, 60, 80, 100, 120, 140, 140, 140 and 140 mg/kg) at 8 h 
intervals. The animals were killed 2 h after the final injection of 
morphine and their vasa were rapidly removed and placed in Krebs solu-
tion containing normorphine (300 nM). Experiments on vasa from 
morphine-pretreated mice were completed within 5 h of removing the 
tissue from ~he animal. 
The tissues from morphine-pretreated mice were maintained in 
Krebs solution containing normorphine to approximate the in vivo condi-
tion in which morphine is continuously present (North & Karras, 1978a) 
and to prevent the withdrawal and rapid loss of tolerance which occurs 
in the mouse vas deferens upon was~ing the tissue with opiate-free 
Krebs solution (Cox, 1978). The reasons for using a concentration of 
normorphine of 300 nM were two-fold. Firstly, this concentration is 
similar to the concentration used by Schulz & Herz (1976) in their 
study of morphine tolerance in the guinea-pig ileum. They found that 
normorphine (200 nM) ideally maintained tissues removed from morphine-
pretreated animals in a state of tolerance and dependence. Secondly, 
by maintaining a tissue in a concentration of 300 nM, a normorphine 
dose-response curve can be completed without exceeding a 10 ~M concen-
tration. Morphine in concentrations above 10 ~M inhibits noradrenaline 
uptake in adrenergic nerves by an action unrelated to the opiate 
receptor (Montel & Starke, 1973). 
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2.7 Effects of cyclic nucleotides and phosphodiesterase inhibitors 
The acute effects of the cyclic nucleotide cAMP and the dibutyryl 
derivative of cAMP (dbcAMP), and the acute effects of the phospho-
diesterase inhibitors IBMX and SQ 20,006 on the amplitude of the evoked 
e.j.p. were determined. The effect of normorphine on e.j.p. amplitude 
was tested on tissues superfused with cAMP (1 mM) and on tissues super-
fused with the drug combination dbcAMP (500 ~M) and IBMX (50 ~M). The 
effects of D-Ala2-Met5-enkephalinamide (DAEA) and D-Ala2-D-Leu5-
enkephalin (DADL) on e.j.p. amplitude were tested on tissues superfused 
with both IBMX (500 ~M) and dbcAMP (250 ~M). 
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2.8 Effects of altered concentrations of calcium ion 
The alteration of e.j.p. amplitude caused by halving or doubling 
the normal calcium ion concentration (2.54 mM) was determined. In 
these solutions of varying calcium ion concentration, osmolarity was 
maintained by adjusting the concentration of NaCl. Dose-response 
curves for the depression by normorphine of e.j.p. amplitude were 
constructed for vasa maintained in ·calcium ion concentrations of 1.27 
mM, 2.54 mM and 5.08 mM. 
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2.9 Contractions of the vas deferens 
A single vas deferens was suspended in an organ bath (volume 
1.5 ml). The tissue was washed with Krebs solution warmed to 37° C and 
gassed with 95% o2 and 5% C02 ; this solution was of the same ionic 
composition as described above except for the omission of magnesium ion 
(Hughes et al., 1975a). Changes in tension of the vas deferens were 
recorded isometrically. Single stimulus pulses (voltage maximal, dura-
tion 1 ms, frequency 0.1 Hz) were generated by a Grass stimulator 
(model S4K) ·and applied to the tissue across two platinum wire elec-
trodes situated at the top and bottom of the organ bath. The 
effect of normorphine (100 nM - 30 ~M) on the responses of the muscle 
to nerve stimulation was tested. 
Dose-response curves for the contractile response to noradrena-
line were constructed. Noradrenaline doses were given in ascending 
order at 12 min intervals. Noradrenaline (1 ~M- 1 mM) was applied in 
the same location in the organ bath relative to the tissue and in the 
same volume (13 ~1). The largest concentrations tested (3 and 10 mM) 
requ~red larger injection volumes. Stock solutions of noradrenaline 
in Krebs solution were made fresh daily and contained ascorbic acid 
(100 ~M). 
In a few experiments a linear motion transducer was used to 
record the changes in length of the vas deferens in response either to 
field stimulation of the intramural nerves (as above) or to an 
injection of noradrenaline or high potassium solution. 
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2.10 Collection and analysis of data 
The calibration of the oscilloscopes was periodically checked by 
using a square-wave generator. E.j.p. amplitudes _were measured by 
projecting the oscilloscope traces recorded on film onto calibrated 
graph paper by means of a film enlarger. The percentage change in 
e.j.p. amplitude in response to a drug or to a change in ionic compo-
sition of the Krebs solution was determined as follows. After a 
control period of four min or more, the tissue was superfused with drug 
until the ~litude of at least three consecutive e.j.ps remained 
relatively constant (no trend toward an increase or a decrease in 
amplitude was discernible). For each drug application, a plot of 
e.j.p. amplitude vs. time was drawn. E.j.p. amplitudes during the 
control period and during the time of maximum drug effect were deter-
mined by either drawing a line through the data points (estimated by 
eye) or by averaging the measured amplitudes. A drug effect was not 
accepted unless at least a 50% reversal of the effect occurred upon 
returning to control Krebs solution. 
Results were analyzed by calculation of the mean, standard 
deviation and standard error of the mean using standard formulae 
(Goldstein, 1964). Student's t test was used to compare the means of 
two groups which received different experimental treatments. One-way 
analysis of variance (ANOVA) was used to compare the means of three or 
more groups. A p value greater than 0.05 was chosen to indicate 
statistical significance. 
2.11 Drugs 
Drugs used were: adenosine (Sigma), adenosine 3' ,5 1-cyclic 
monophosphoric acid (Sigma), D-Ala2-D-Leu5-enkephalin (Biosearch), 
D-Ala2-Met5-enkephalinamide (Peninsula), N6 , 021 -dibutyryl adenosine 
3' ,5'-cyclic monophosphoric acid, sodium salt (Sigma), l-ethyl-4-
hydrazino-1H-pyrazolo(3,4-b)pyridine-5-carboxylic acid, ethyl ester, 
hydrochloride (SQ 20,006) (Squibb), 1-methyl-3-isobutylxanthine 
(Sigma), dl-noradrenaline hydrochloride (dl-arterenol) (Sigma), 
morphine sulphate (Lilly), naloxone hydrochloride (Endo Laboratories) 
and normorphine sulphamate (Dr. A. E. Jacobson). 
Molar concentrations refer to the final bath concentration of 
these substances. 
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3. RESULTS 
3.1 General observations 
The results of the present study are based on recordings from 363 
cells (152 mice). Recordings from single cells of up to 3.5 h were 
possible, although the usual duration of impalement was 20 min to 1 h. 
The resting membrane potential of individual smooth muscle cells was 
62.6 ± 0.9 mV (mean+ s.e. mean, n = 16). 
E.j.ps evoked by field stimulation of the intramural nerves of 
the vas deferens could be recorded in every cell successfully impaled; 
their amplitudes were dependent on the stimulus strength. At a fixed 
stimulus duration, the stimulus voltage used to evoke an e.j.p. of a 
given amplitude (about 15 mV) varied from one tissue to the next, and 
among cells in the same tissue. The voltage for a given cell depended 
on: the initial positioning of the platinum ring electrodes around the 
muscle, the location of the cell relative to the electrodes, the posi-
tion of the recording electrode and the depth of the Krebs solution 
flowing through the tissue bath. 
The time to peak amplitude for an e.j .p. was 25-45 ms, and the 
time to decay to one-half the peak amplitude was 60-90 ms. The rising 
phase of the depolarization was steeper in slope and shorter in 
duration than the falling phase (Figure 2). In some cells graded 
action potentials were observed; these events could occur on the rising 
phase, peak or falling phase of an e.j.p. If these potentials obscured 
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Figure 2. Photographs of excitatory junction potentials (e.j.ps). 
Photographs of oscilloscope tracings illustrating the waveform and 
time course of,an e.j.p., and the depression of e.j.p. amplitude by 
normorphine. In this cell, normorphine (1 ~M) decreased e.j.p. 
amplitude ·by 68%,' from 22-mV to 7 mV. This effect washed within 5 
min of resuming superfusion with drug-free Krebs solution. 
100 
ms 
101' 
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CONTROL NOR (1 ;-tM) WASH 
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the peak amplitude of the e.j.p. in a cell, the cell was not used for 
experimentation. 
Spontaneous junction potentials were observed in almost every 
cell, although their frequency was markedly variable among cells and 
tissues. 
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3.2 Effect of opiates and opioid peptides 
3.21 Normorphine 
Normorphine (100 nM - 30 ~M) depressed the amplitude of the 
evoked e.j.p. (Figure 2) but did not alter the resting membrane poten-
tial of the smooth muscle cells. Any effect of a drug on membrane 
potential would be obvious if the change were greater than 3-5 mV. 
This effect of normorphine was maximal 4-8 min after the onset of drug 
superfusion, and usually washed within 5-15 min of resuming superfusion 
with drug-f~ee Krebs solution. The magnitude of the depression of the 
e.j.p. by normorphine was larger with higher concentrations of normor-
phine. A composite dose-response curve for normorphine was constructed 
by pooling results from many cells. Because the duration of impale-
ments was variable, it was not always possible to test all concentra-
tions of normorphine on the same tissue. Occasionally, however, all 
normorphine concentrations were tested even on a single cell. The Ec50 
for normorphine (concentration that depressed the e.j.p. to 50% of its 
control amplitude) was 570 nM (Figure 3). An e.j.p. that was depressed 
in amplitude by normorphine could be restored to its control amplitude 
by increasing the stimulus voltage. 
3.22 Normorphine at different stimulus strengths 
Many of the experimental protocols of the present study involved 
testing the effect of opiates or opioid peptides on vasa which have 
been exposed to substances or ionic conditions which themselves altered 
e.j.p. amplitude. Under these conditions the stimulus strength was ad-
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Figure 3. Dose-response curves for depression of e.j.p. by normor-
phine and opi~id peptides. A comparison of the dose-response curves 
for depres~ion bf e.j.p: amplitude by normorphine (NOR), D-Ala2-Met5-
enkephalinamide (DAEA) and D-Ala2-D-Leu5-enkephalin (DADL). Bars 
represent + standard deviation. Numbers in parentheses indicate the 
number of individual cells tested at a given concentration. 
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justed in order to obtain a control e.j.p. of approximately 15 mV in 
amplitude before testing the effect of an opiate or opioid peptide. It 
was therefore necessary to investigate if the potency of normorphine 
was dependent on the initial amplitude of the e.j.p. and on the stim-
ulus strength necessary to evoke it. Normorphine (100 nM, 300 nM and 
1 ~M) was tested on both high amplitude and low amplitude e.j.ps, often 
on the same cell or tissue. The degree of depression of the high 
amplitude e.j.ps (35 mV) was the same as the degree of depression of 
low amplitud~ e.j.ps (10 mV) by a given concentration of normorphine 
when the results from many cells and tissues were pooled. These compo-
site results are summarized in Table la. Also, for a given individual 
cell, normorphine (1 ~M) was equally effective in depressing the e.j.p. 
regardless of the control e.j.p. amplitude in the range 9-38 mV 
(Table lb). 
3.23 Prolonged exposure to normorphine in vitro 
Some vasa were incubated in Krebs solution containing normorphine 
(300 nM) for 1-5 h, and the effect of higher concentrations of normor-
phine (1 and 3.~M) on e.j.p. amplitude was then tested. An example of 
such an experiment is illustrated in Figure 4. The potency of normor-
phine (3 ~M) in causing a depression of e.j.p. amplitude in vasa main-
tained in Krebs solution containing normorphine (300 ru~) was not 
different from its potency in vasa maintained in drug-free Krebs 
solution. Normorphine (1 ~M) was less effective in the vasa exposed to 
opiate drug in vitro (Table 2). 
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Table 1. Effect of e.j.p. amplitude and stimulus voltage on 
depression of e.j.p. by normorphine. (a) Composite results. 
*Mean± s.e. m~an. Numbers in parentheses indicate the number of 
cells tested. Depression of high amplitude e.j.p. vs. depression 
of low amplitude 'e.j.p. was the same for all three concentrations 
of normorphine (100 nM, 300 nM and 1 ~M) (Students's t test, 
p>0.05). (b) Results from three cells. There was no change in the 
degree of depression caused by normorphine (1 ~M) if tested on 
e.j.ps of different amplitudes recorded in the same cell. E.j.p. 
amplitude was changed by increasing or decreasing the stimulus 
strength. 
Table 1. 
(a) Composite results 
(b) 
NORMORPHINE (100 nM): 
Large amplitude e.j.p. 
Small amplitude e.j.p. 
NORMORPHINE (300 nM): 
Large amplitude e.j.p. 
Small amplitude e.j.p. 
NORMORPHINE (1 ].!M): 
Large amplitude e.j.p. 
Small amplitude e.j.p. 
Individual cells 
Stimulus 
Cell II Voltage 
4209-2 1.3 
" 7.6 
4279-2 1.0 
" 10.0 
" 17.0 
4309-1 10.4 
" 23.0 
Amplitude of 
e. j . p. (mV) * 
35.5 + 1.8 mV 
10.4 + 0. 9 mV 
35.3 + 1.2 mV 
10.7 + 0.8 mV 
34.0 + 2.1 mV 
11.4 + 1.3 mV 
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Percent depression 
of e.j.p.* 
-17 + 5.2% (7) 
-19 + 5.8% (6) 
-39 + 5.0% (6) 
-46 + 3.6% (6) 
-73 + 3.2% (6) 
-66 + 5.3% (6) 
Percent depression 
Amplitude of of e.j.p. by 
e.j .p. (mV) Normorphine (1 ].JM) 
10 75 
26 73 
9 54 
16 63 
36 65 
10 84 
38 87 
76 
Figure 4. Effect of normorphine (1 and 3 ~M) on e.j.p. after 
prolonged superfusion with normorphine (300 nM) in vitro. This 
tissue had been .maintain~d in Krebs solution containing normor-
phine (300 nM) for 4 h at time zero, and normorphine (300 nM) was 
also present throughout the recording period. During superfusion 
with normorphine (1 ~M) for 5 min, the e.j.p. was depressed by 50%. 
During superfusion with normorphine (3 ~M), also for 5 min, the 
e.j.p. was depressed by 78%. 
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Table 2. Effect of superfusion with drug-free Krebs solution vs. Krebs 
solution containing normorphine (300 nM) on depression of e.j.p. by 
normorphine (1 and 3 ~M). The depression by normorphine (1 and 3 ~M) 
of amplitudes of evoked e.j.ps was measured in vasa maintained in drug-
free Krebs solution or in vasa maintained in Krebs solution containing 
normorphine (300 nM) for 1-5 h. *Mean+ s.e. mean. Numbers in paren-
theses indicate the number of cells tested at a given concentration. 
Values from vasa maintained in drug-free Krebs solution and values from 
vasa maintai~ed in normorphine-containing Krebs solution were signifi-
cantly different for normorphine (1 ~M) (Student's t test; p<O.Ol) but 
not for normorphine (3 ~M). 
Vasa maintained in drug-
free Krebs solution 
Vasa maintained in Krebs 
solution containing 
normorphine (300 nM) 
Percent depression of e.j.p.* 
Nor (1 ~M) Nor (3 ~M) 
66 + 1.5% (16) 78 + 1.8% (8) 
54 + 2.1% (8) 76 + 1.5% (8) 
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3.24 DAEA 
DAEA (10-300 nM) decreased the amplitude of the e.j .p. DAEA did 
not alter the resting membrane potential of the smooth muscle cells. 
The effect of DAEA on e.j .p. amplitude was maximal within 4 min of the 
onset of drug superfusion, and quickly reversed (4-6 min) after drug 
washout. The dose-response curve for the depression of the e.j.p. by 
DAEA is shown in Figure 3; the EC50 for this action of DAEA was 50 nM. 
3.25 DADL 
DADL (300 pM- 3 nM) decreased the amplitude of the evoked e.j .p. 
but did not change the resting membrane potential of the smooth muscle 
cells. Although the maximum effect of this peptide consistently 
occurred within 4-7 min after onset of superfusion, the time required 
for washout was variable. In some tissues the e.j.p. amplitude re-
turned to its control amplitude within 5-10 min of resuming superfusion 
with drug-free Krebs solution. Usually, however, the effect of the 
higher concentrations of DADL tested (1 and 3 ~~) did not completely 
reverse, even after prolonged washing (20 min or more). The Ec50 for 
the depression of e.j.p. amplitude by DADL was 500 pM (Figure 3). 
3.26 Naloxone 
Naloxone (up to 1 ~M) did not change the resting membrane poten-
tial of single smooth muscle cells, nor did it change the amplitude of 
the e.j.p. Naloxone (300 nM) reversed the depression of the e.j.p. 
caused by superfusion with normorphine (300 nM). Normorphine (300 ru~) 
depressed the e.j.p. by an average of 32% (Figure 3). Naloxone 
(300 nM) reversed this depression, but the e.j.p. amplitude never 
increased to more than its control value prior to administration of 
normorphine (Figure 5). In vasa acutely exposed to normorphine 
(300 nM, for 10 min or less), naloxone increased e.j.p. amplitude by 
64 + 11% (n = 8). The largest effect observed was a doubling of the 
e.j.p. in an experiment in which normorphine originally caused a 
halving of its amplitude. 
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Naloxone was also tested on vasa that were maintained for 5-8 h 
in Krebs solution containing normorphine (300 nH). Cells from these 
preparations responded to naloxone (300 nM) with an increase in e.j.p. 
amplitude of 184 + 21% (n = 4). 
3.27 Contractions of the muscle 
Short-duration increases in tension of the muscle ("twitches") 
of the vas deferens occur in response to field stimulation of the 
intramural nerves. The height of the muscle twitches decreased if 
normorphine (final bath concentration 100 nM - 1 ~M) was injected into 
the bath. The normorphine Ec50 was 240 + 44 nM (n = 5). 
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Figure 5. Reversal by naloxone of effect of normorphine on e.j.p. 
The amplitude of the e.j.p. was depressed by approximately 50% after 
5 min of ~xposure to normorphine (300 nM). This effect was subse-
quently reversed within 2 min of superfusion with naloxone (300 nM) 
despite the continued presence of the normorphine. 
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3.3 Effect of adenosine and cyclic nucleotides 
3.31 Adenosine 
Adenosine (300 ~M and 1 mM) depressed the amplitude of the evoked 
e.j.p. without changing the resting membrane potential of the smooth 
muscle cells. This effect was rapid in onset and offset (2-5 min). 
The magnitude of the effect of adenosine (1 mM) did not diminish if the 
substance was repeatedly applied to the same cell at intervals of 10-15 
min. Adenosine (300 ~M) depressed the e.j.p. by 42 ± 3.0% (n = 11), 
whereas adenosine (1 mM) depressed it by 64 ± 3.3% (n = 13). 
3.32 Cyclic AMP and dbcAMP 
The resting membrane potential of single smooth muscle cells was 
not changed by the addition of cAMP or dbcAMP (up to 1 mM) to the 
superfusing solution; both of these substances, however, depressed the 
amplitude of the e.j.p. The effect of the cyclic nucleotides, like 
that of adenosine, was rapid in onset and offset (2-5 min). The effect 
did not diminish with repeated drug applications (at 10-15 min inter-
vals) to the same cell or tissue, as illustrated for cAMP (1 mM) in 
Figure 6. Cyclic AMP (1 mM) decreased the e.j.p. amplitude by 52± 
3.9% (n = 9). The e.j.p. was decreased by 13% and by 30% in the two 
cells on which cAMP (300 ~M) was tested; cAMP (100 ~M) had no effect 
(two cells). DbcAMP (1 mM) decreased e.j.p. amplitude by 22.5 + 3.7% 
(n = 8); lower concentrations of this substance were not tested. 
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Figure 6. Comparison of effect of cAMP with effect of normorphine on 
e.j.p. During the first application (for 5 min) of cAMP (1 mM), the 
e.j.p. was. dep~ssed by 57%. The second application (also for 5 min) 
of the same concentration of cAMP 10 min later resulted in a 61% 
depression of the e.j.p. 'The amplitude of the e.j.p. was decreased by 
66% after 7 min of superfusion with normorphine (1 ~M). In this cell, 
normorphine was about 1,000 times more potent than cAMP. 
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3.4 Effect of phosphodiesterase inhibitors 
3.41 IBMX or SQ 20,006 alone 
Neither the xanthine IBMX nor the non-xanthine SQ 20,006 (up to 
1 mM) altered the resting membrane potential of smooth muscle cells, 
but both increased the amplitude of the e.j.p. This increase was slow 
in onset, reaching its maximum after 8-12 min of drug superfusion, and 
subsequently was slow to reverse upon washing (15-30 min). IBMX 
(50 ~M) increased e.j.p. amplitude 58± 9% (n = 6) and IBMX (500 ~M) 
increased it 167 ± 20% (n = 7). A second application of a given con-
centration of IBMX to the same cell or preparation (after 15 min - 3 h) 
was less effective than the initial application (Table 3). SQ 20,006 
(500 ~M) enhanced e.j.p. amplitude by 54+ 13% (n = 5). 
3.42 The combination phosphodiesterase inhibitor and dbcAMP 
DbcAMP alone weakly depressed the e.j.p., whereas IBMX increased 
the e.j.p. (see above). But IBMX and dbcAMP applied together were more 
effective than IBMX alone in increasing the e.j.p. (Figure 7). Thus 
IBMX (50 ~M) in combination with dbcAMP (500 ~M) increased e.j.p. 
amplitude by 103 ± 16% (n = 5). Also, IBMX (500 ~M) + dbcAl~ (250 ~M) 
increased it by 182 ± 21% (n = 5). The combination IBMX (500 ~M) + 
dbcAMP (500 ~M) increased it by an average of 285% (n = 3). These 
effects on e.j.p. amplitude were larger in magnitude than those ob-
tained by application of IBMX (50 or 500 ~M) alone (Table 3). In one 
experiment dbcAMP (1 mM), applied during superfusion with IBMX (50 ~M) 
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Table 3. Increase of e.j.p. amplitude by IBMX: effect of concen-
tration and repeated application. *Mean+ s.e. mean. Numbers in 
parentheses indicate the number of individual cells tested. The effect 
of IBMX (superfused for 10-15 min) on its second application was less 
than that on its first application at both concentrations tested 
(Student's t test; p<O.Ol). 
Increase of e .j .p. Increase of e .j. P. 
Concentration amplitude (%) * amplitude (%)* 
of IBMX First application Second application 
50 llM 58 + 9% (6) 12 + 6% (5) 
500 llM 167 + 20% (7) 82 + 10% (6) 
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Figure 7. Comparison of effect of IBMX alone with effect of drug 
combination IBMX + dbcAMP on e.j.p. E.j.p. amplitude vs. time is 
plotted as a histogram.· Each bin is the average of the amplitudes of 
three consecutive e.j.ps. The second application of IBMX (50 ~M) to 
this tissue (for 6 min) resulted in a 32% increase of the e.j.p. (the 
first application is not shown). Subsequent exposure of the cell to 
both IBMX (50 ~M) and dbcAMP (1 mM) for 6 min produced an increase in 
e.j.p. amplitude of 95%. 
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and after the effect of IBMX was maximal, increased e.j.p. amplitude by 
59%. 
The drug combination SQ 20,006 and dbcAMP was also more effective 
than SQ 20,006 alone (Figure 8). SQ 20,006 (500 ~M) + dbcAMP (250 ~M) 
increased e.j.p. amplitude by 392 + 43% (n = 4); by itself, this con-
centration of SQ 20,006 had only a small effect (see above). 
In a few experiments the effect of the drug combination IBMX and 
dbcAMP was tested on the isotonic contractions of the smooth muscle of 
the vas deferens. The contraction produced by electrical stimulation 
of the intramural nerves was reduced by superfusion with Krebs solution 
containing IBMX (500 ~M) and dbcAMP (250 ~M). Contractile responses to 
exogenous noradrenaline (10 ~M) and to high potassium solution (50 mM 
KCl) could not be elicited in the presence of these two compounds. 
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Figure 8. Comparison of effect of SQ 20,006 alone with effect of drug 
combination SQ 20,006 + dbcAMP on e.j.p. A 12 min exposure to 
SQ 20,006 ~500 ~M) produced only a small increment in e.j.p. amplitude 
(37%) in this cell. Subsequent superfusion (also for 12 min) with the 
same concentration of SQ 2b,006 in combination with dbcAMP (250 ~M) 
resulted in a dramatic 336% enhancement of the amplitude of the e.j.p. 
The effect of these substances in combination was not apparent until 
at least 5 min after switching to the drug-containing solution (dead 
time was about 1 min), and was also slow to reverse. E.j.p. amplitude 
returned to its control value only after 30 min of washing with drug-
free Krebs solution. 
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3.5 Effect of altered calcium ion concentration 
Doubling the calcium ion concentration of the Krebs solution (to 
5.08 mM) resulted in an increase in e.j.p. amplitude of 144 + 20% 
(n = 5), whereas halving it (to 1.27 mM) resulted in a decrease in 
e.j.p. amplitude of 66 + 4.9% (n = 6). These effects of altered 
calcium ion concentration stabilized within 5-12 min of changing the 
Krebs solution, and reversed within 10-15 min of resuming superfusion 
with control Krebs solution (Figure 9). When the calcium ion concen-
tration was doubled or halved, changes in the membrane potential of the 
smooth muscle cells were less than 5 mV. 
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Figure 9. Effect of doubling the calcium ion concentration on e.j.p. 
The amplitude of the e.j.p. in this cell increased almost three-fold 
(192%) durfng a 15 min superfusion with Krebs solution containing 
twice the normal calcium ion concentration. The effect of the changed 
solution peaked after 10 ffiin and washed within 10-15 min. 
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3.6 Effect of prolonged exposure to morphine in vivo 
In order to assess the effect of prolonged exposure to morphine 
on neuro-effector transmission in the mouse vas deferens, vasa from 
mice that had received morphine injections for three d (see Methods) 
were studied. Vasa from these mice were compared to vasa from naive 
mice which received no injections with respect to: resting membrane 
potential of smooth muscle cells, effects of normorphine, adenosine and 
naloxone on the e.j.ps, and contractions of the muscle in response to 
noradrenalin~. 
3.61 Membrane potentials 
The resting membrane potential of individual smooth muscle cells 
was 63.0 + 2.1 mV (n = 11) in vasa from morphine-pretreated animals. 
This value was not significantly different from the value of the 
resting membrane potential in single cells of vasa from naive mice 
(62.6 ± 0.9 mV)(Student's t test). Morphine pretreatment produced no 
obvious change in the frequency and/or amplitudes of spontaneous 
junction potentials, although careful measurements were not made. 
3.62 Normorphine 
Vasa from morphine-pretreated mice were maintained in Krebs solu-
tion containing normorphine (300 nM) (see Methods). Normorphine (1-30 
~M) did not alter the resting membrane potentials of the smooth muscle 
cells. Normorphine (1 ~M) did not depress the e.j .p. in cells from 
these vasa (Figure 10) . Higher concentrations of normorphine (3-30 ~M) 
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Figure 10. Effect of normorphine (1 ~M) on e.j.p. (morphine-
pretreated mouse). This tissue had been maintained in Krebs solution 
containin~ normorphine.(300 nM) for 80 min at time zero; this concen-
tration of normorphine was also present throughout the recording 
period. Application of normorphine (1 ~M) for 6 min had no effect on 
the amplitude of the e.j.p. 
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decreased the amplitude of the e.j.p. (Figure 11) with a time course 
similar to the time course of action in vasa from naive mice. The 
dose-response curve for depression of e.j.p. amplitude by normorphine 
in vasa from morphine-pretreated mice was shifted to the right of the 
dose-response curve for this action of normorphine in vasa from naive 
mice (Figure 12). The Ec 50 for normorphine in vasa from morphine-
pretreated mice was 6.6 ~M (compared to 560 nM in vasa from naive 
mice). Individual EC50 values for tissues exposed to morphine in vivo 
ranged from 3 to 30 ~M, and did not overlap with individual EC50 values 
in vasa from naive mice (270- 890 nM). Depressions of e.j.p. ampli-
tude by normorphine of 80-90% could be obtained in vasa from both 
groups of animals. 
3.63 Adenosine 
Adenosine (300 ~M and 1 mM) decreased e.j.p. amplitude without an 
effect on the resting membrane potential. The effect had the same 
rapid time course (onset and offset of action within 2-5 min) in 
tissues from morphine-pretreated mice as in vasa from naive mice 
(Figure 13). Adenosine (300 ~M) depressed the e.j.p. by 40 ± 6.0% 
(n = 8). Adenosine (1 mM) depressed the e.j.p. by 70 ± 4.4% (n = 9). 
The magnitude of these effects of adenosine in vasa from morphine-pre-
treated mice did not differ from the magnitude of the effects of adeno-
sine in vasa from naive mice (Table 4). 
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Figure 11. Effect of normorphine (3 and 10 ~M) on e.j.p. (morphine-
pretreated mouse). This tissue had been maintained in Krebs solution 
containin& normorphine ·(300 nM) for 2 h at time zero, and throughout 
period of recording. The e.j.p. amplitude was decreased by 20% by a 
10-fold increase in the normorphine concentration of the Krebs solu-
tion (from 300 nM to 3 ~M) for 5 min. In this tissue, the e.j.p. was 
reduced 50% by normorphine (10 ~M), applied for 5.5 min. Compare 
these results with those illustrated in Figure 4. 
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Figure 12. Normorphine dose-response curves for depression of e.j.p.: 
naive mice vs. morphine-pretreated mice. Vasa from morphine-
pretreated mice were ma~ntained in Krebs solution containing normor-
phine (300 nM). Bars represent+ s.e. mean. Numbers in parentheses 
indicate the number of individual cells tested at a given concentra-
tion. 
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Figure 13. Effect of adenosine on e.j.p. (morphine-pretreated mouse). 
Adenosine (300 ~M) decreased the e.j.p. from 16 mV to 10.5 mV (a 34% 
depression) whereas adenosine (1 mM) decreased it from 18 mV to 6 mV 
(a 67% depression). Both concentrations were applied for 5 min. The 
onset and offset of these 'effects in this cell were rapid (2 min), and 
were typical of the time course of the effects of adenosine on cells 
from both naive and morphine-pretreated tissues. 
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Table 4. Depression of e.j.p. by adenosine in vasa from naive and 
morphine-pretreated mice. *Mean+ s.e. mean. Numbers in parentheses 
indicate the number of cells tested at a given concentration. There 
was no difference between values in control (naive) mice and morphine-
pretreated mice at either concentration (Student's t test). 
Control (naive) mice 
Morphine-pretreated mice 
Percent inhibition of e.j.p.* 
Adenosine (300 uM) 
42 + 3.0% (11) 
40 + 6.0% (8) 
Adenosine (1 mM) 
64 + 3.3% (13) 
70 + 4.4% (9) 
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3.64 Naloxone 
Naloxone (up to 1 ~M) did not alter the resting membrane poten-
tial of the smooth muscle cells; nor did it cause any marked change in 
the frequency of spontaneous e.j.ps when it was applied to the vasa 
from morphine-pretreated mice. In these vasa (maintained in Krebs 
solution containing normorphine), changing to a solution that contained 
both normorphine (300 ru~) and naloxone (300 nM) caused a large increase 
in the amplitude of the e.j.p. (Figure 14). This effect was observed 
in 9 cells from 9 different tissues; the average increase in e.j.p. 
amplitude was 360 + 37% (range 254% to 600%). The increase in e.j.p. 
amplitude peaked within 3-5 min of the addition of naloxone to the 
superfusing Krebs solution, but the effect was slow to reverse (Figure 
14). In most instances the impalement was terminated before the e.j.p. 
amplitude returned to its pre-naloxone value. 
3.65 Drug-free Krebs solution 
The superfusion of vasa from morphine-pretreated mice (maintained 
in Krebs solution containing normorphine) with normorphine-free Krebs 
solution caused an increase in the amplitude of the e.j.p. In the 
three cells from three different tissues that were tested in this 
manner, application of drug-free Krebs solution (for 8-11 min) 
increased e.j.p. amplitude by 365%, 240% and 100% respectively. 
108 
Figure 14. Effect of naloxone on e.j.p. (morphine-pretreated mouse). 
Normorphine (~00 nM) was present throughout the recording period and 
for 4 h p~eviodsly at time zero. The addition of naloxone (300 nM) 
to the superfusing Krebs solution (for 5 min) caused a 7-fold (600%) 
< 
increase in the e.j.p. This effect was slow to reverse upon washing 
out the naloxone. A second application of naloxone (300 nM) to the 
cell was again effective in enhancing the e.j.p. amplitude, although 
the recording was prematurely terminated before the magnitude and 
duration of this second effect could be ascertained. 
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3.66 Contractions of the muscle 
The contractions of the smooth muscle of the vas deferens in 
response to exogenous noradrenaline were measured for tissues prepared 
from both naive and morphine-pretreated mice. When noradrenaline (1 ~M 
- 10 mM) was added to the organ bath, the vas deferens developed an in-
crease in tension which peaked rapidly and then declined before washout 
of the drug, The rate of change of tension increased with increasing 
drug concentration, provided the tip of the injecting needle was in the 
same position in the organ bath relative to the tissue. With high con-
centrations of noradrenaline (100 ~M- 10 mM), the initial peak tension 
was followed by a series of rapid fluctuations in tension of lower 
amplitude. Only the initial peak response was measured. Dose-response 
curves for these responses of the vasa to noradrenaline were con-
structed for vasa from both morphine-pretreated and naive mice (Figure 
15). The noradrenaline Ec50 (concentration producing a peak tension 
which was one-half of the maximum response to this substance) was 10.4 
~M in vasa from morphine-pretreated mice and 10.5 ~M in vasa from naive 
mice. The maximum response of the tissue to noradrenaline (expressed 
as mg tension/10 mg wet weight of tissue) was 2,044 ± 106 (n = 8) in 
vasa exposed to morphine in vivo and 1,851 + 109 (n = 13) in vasa from 
naive mice. These values were not significantly different (Student's t 
test). The wet weight of the vasa from morphine-pretreated mice (11.5 
± 0.6 mg, n = 8) also was not different (Student's t test) from the wet 
weight of vasa from naive mice (12.7 ± 0.5 mg, n = 14). 
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Figure 15. Dose-response curves for contractile responses of the 
smooth muscle to noradrenaline: vasa from naive mice vs. vasa from 
morphine-p~etreated mice. Bars indicate+ s.e. mean. Numbers in 
parentheses indicate the number of tissues tested with a given concen-
tration. At all concentrations, differences between values from 
control animals and values from morphine-pretreated animals were com-
pared using Student's t test. Only at one concentration of noradren-
aline (1 mM) were these values significantly different (p = 0.04). 
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The nerve-mediated muscle twitches of vasa from morphine-pre-
treated mice were inhibited by normorphine (1-30 ~M). Individual 
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Ec50 values for normorphine were determined for six vasa from morphine-
pretreated mice and ranged from 1.6 ~M to 7.8 ~M. The normorphine Ec50 
was 4,000 ± 890 nM (n = 6), which was significantly different from the 
Ec50 for the inhibition by normorphine of the muscle twitches in vasa 
from naive mice (240 + 44 nM). 
3.7 Effect of cyclic nucleotides and IBMX on the actions of 
normorphine and opioid peptides 
3.71 Normorphine 
114 
The effect of normorphine on e.j.p. amplitude was measured in 
vasa superfused with cAMP (1 mM) and compared to its effect in vasa 
that were not treated with this substance. This concentration of cAMP 
depressed e.j.p. amplitude by 52± 3.9% (see above). The tissue was 
superfused w~th c&~ (1 w~) for 5-30 min before testing normorphine. 
Stimulus voltage was adjusted prior to the application of cAMP so that 
the e.j.p. was between 10 and 25 mV in amplitude before the application 
of normorphine. Normorphine decreased e.j.p. amplitude in the presence 
of cAMP (1 mM), with a time course of onset and offset of action 
similar to its effect in the absence of this nucleotide in other vasa. 
The Ec50 for depression of e.j.p. amplitude by normorphine in the 
presence of cAMP (1 mM) was 700 nM, as determined from the composite 
dose-response curve (Figure 16). For comparison, the dose-response 
curve for normorphine in vasa not treated with cyclic nucleotide is 
also illustrated in this figure. 
Normorphine was also tested in preparations that had been super-
fused with both IBMX (50 ~M) and dbc&~ (500 ~M) for at least 12 min. 
This drug combination increased e.j.p. amplitude by 103 + 16%, as 
determined by testing on other tissues (see above). Normorphine still 
decreased e.j.p. amplitude in the presence of these substances and the 
time course of onset of its effect was not changed. Often the reversal 
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Figure 16. Normorphine dose-response curves for depression of e.j.p.: 
effect of cAMP. and the drug combination IBMX + dbck~. Dose-response 
. 
curves for•normorphine were constructed using results from tissues 
that were not pretreated with any drugs, results from tissues exposed 
to cAMP (1 mM) and results from tissues pretreated with IBMX (50 ~M) 
+ dbcAMP (500 ~M). Bars represent+ s.e. mean. The number of indi-
vidual cells tested at each concentration was at least six. Control 
values and values after incubation in cAMP or incubation in the drug 
combination IBMX + dbcAMP were compared by one-way analysis of 
variance at three concentrations (300 nM, 1 ~M and 3 ~M). No signi-
ficant effect of these substances on the response to normorphine was 
found. 
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of the depression of the e.j.p. caused by normorphine was faster in 
vasa superfused with IBMX + dbcAMP (Figure 17) than in vasa not treated 
with these substances. The dose-response curve for normorphine in 
tissues superfused with both IBMX (50 ~M) and dbcAMP (500 ~M) was vir-
tually superimposable on the dose-response curve obtained from tissues 
not exposed to these substances (Figure 16). The normorphine EC50 was 
590 nM for tissues exposed to IBMX (50 ~M) + dbcAMP (500 ~M), as com-
pared to 560 nM in drug-naive preparations. 
3.72 DAEA 
The effect of DAEA on e.j.p. amplitude was tested on vasa exposed 
to both IBMX (500 ~M) and dbc&~ (250 ~M) for 12 min or more, and com-
pared to the effect of DAEA on vasa not so treated. In other experi-
ments, IBMX and dbcAMP applied together in these concentrations 
increased e.j.p. amplitude by 182 ± 21% (see above). DAEA (10-300 nM) 
still decreased e.j.p. amplitude in the presence of IBMX + dbcAMP 
(Figure 18) ; the time course of this effect was the same as in un-
treated tissues. The potency of DAEA was slightly enhanced in tissues 
exposed to IBMX + dbcAMP compared to control tissues, as is evident 
from the composite dose-response curves (Figure 19). The magnitude of 
the effect of DAEA in tissues exposed to IBMX + dbcAMP was signifi-
. cantly different from the magnitude of the effect in control tissues at 
two concentrations (10 nM: p<O.Ol; 100 nM: p<O.OS; Student's t test). 
The EC50 for DAEA in vasa superfused with IBMX + dbc.~ was 27 nM, 
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Figure 17. Effect of normorphine (1 ~M) on e.j.p. in absence and 
presence of IBMX (50 ~M) + dbcAMP (250 ~M): same cell. During the 
time perio@ indicated by the striped bar and dotted line, stimulus 
voltage was adjusted (from 23 to 16 volts) to offset the increase of 
the e.j.p. caused by IBMX + dbcAMP. Normorphine (1 ~M) depressed 
e.j.p. amplitude by 55% in the control solution and by 52% after 12 
miri of superfusion with the combination of IBMX + dbcAMP. The effect 
of normorphine washed out faster during exposure to IBMX + dbcAMP. 
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Figure 18. Effect of DAEA on e.j.p. during superfusion with IBMX + 
dbcAMP. This tissue was exposed to IBMX (500 ~M) and dbc&~ (250 ~M) 
throughout. the 'period of recording, as well as for 12 min previous to 
time zero. DAEA (10-300 nM) decreased the e.j.p. amplitude in this 
' 
cell, and the magnitude of the effect was larger for the higher con-
centrations. 
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Figure 19. Dose-response curves for depression of e.j.p. by DAEA: 
effect of IBMX + dbcAMP. These dose-response curves were constructed 
. 
using results from tissues not exposed to any drugs and results from 
tissues superfused with the drug combination IBMX (500 ~M) and dbcAMP 
(250 ~M). Bars represent~ s.e. mean. Numbers in parentheses indi-
cate the number of individual cells tested at a given concentration. 
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whereas the EC50 for DAEA in control vasa was 50 nM. 
3.73 DADL 
The effect of DADL on e.j.p. amplitude was tested on vasa super-
fused with both IBMX (500 ~M) and dbcAMP (250 ~M) for 12 min or more, 
and compared to the effect of DADL on control tissues. This combina-
tion of IBMX + dbcAMP increased the e.j.p. amplitude (see above). DADL 
(300 pM- 3 nM) decreased the amplitude of the e.j.p. in the presence 
of IBMX + db~AMP (Figure 20) ; the time course of this effect was the 
same as in untreated tissues. Composite dose-response curves for DADL 
in tissues superfused with IBMX + dbcAl~ and in control tissues are 
illustrated in Figure 21. There were no significant differences 
between values from these two groups of vasa (Student's t test). The 
Ec50 for DADL in the treated vasa was 540 pM and the Ec50 in control 
vasa was 500 pM. 
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Figure 20. Effect of DADL on e.j.p. during superfusion with IBMX + 
dbcAMP. This.tissue was exposed to IBMX (500 ~M) + dbcAMP (250 ~M) 
throughout.the period of recording, as well as for 12 min previous to 
time zero. In this cell, DADL (300 pM) depressed the e.j.p. by 30%, 
DADL (1 nM) depressed it by 61% and DADL (3 nM) depressed it by 83%. 
It can be seen that the effects of the higher concentrations of the 
peptide tested (1 and 3 nM) did not completely reverse upon returning 
to superfusion with normal Krebs solution. This was characteristic 
of the depressant action of this compound. 
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Figure 21. Dose-response curves for depression of e.j.p. by DADL: 
effect of IBMX + dbcAMP. These dose-response curves were constructed 
using resu~ts from tissues not exposed to any drugs, and results from 
tissues superfused with the drug combination IBMX (500 ~M) and dbck~ 
' (250 ~M). Bars represent± s.e mean. Numbers in parentheses indicate 
the number of individual cells tested at a given concentration. 
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3.8 Effect of altered calcium ion concentration on the action of 
normorphine 
3.81 Stimulus strength adjusted 
129 
The effect of normorphine on e.j.p. amplitude was determined in 
tissues maintained in twice the normal calcium ion concentration (5.08 
mM) for 1-6 h. Doubling the calcium ion concentration increased the 
e.j.p. by 144 ± 20% in other experiments (see above). The stimulus 
voltage was adjusted so that e.j.ps were between 10 and 25 mV in ampli-
tude before testing normorphine; it is presumed that this adjustment 
has compensated for the effect of high calcium on the e.j.p. Normor-
phine decreased e.j.p. amplitude in tissues maintained in high calcium 
solution (Figure 22) and the time course of the effect was not dif-
ferent from its time course in normal calcium solutions. 
The effect of normorphine on e.j.p. amplitude was also measured 
in vasa maintained in one-half the normal calcium ion concentration 
(1.27 mM) for 1-6 h. Halving the calcium ion concentration decreased 
the e.j.p. amplitude by 66 + 4.9% in other experiments (see above). 
Normorphine was tested on e.j.ps 10-25 mV in amplitude; it is presumed 
that the stimulus voltage has been adjusted to compensate for the 
effect of low calcium. Normorphine depressed the e.j.p. in tissues 
maintained in low calcium solution (Figure 23). 
The dose-response curves for the effect of normorphine on e.j.p. 
amplitude in tissues maintained in high calcium (5.08 mM), normal 
calcium (2.54 mM) and low calcium (1.27 mM) solutions are illustrated 
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Figure 22. Effect of normorphine on e.j.p. during superfusion with 
high calcium ~olution. The tissue was superfused with Krebs solution 
containing.calcium (5.0S mM) throughout the recording, and for 4.5 h 
previously. The action of normorphine was related to the concentra-
tion applied, and in this cell the following depressions of e.j.p. 
amplitude occurred: normorphine (100 nM), 26%; normorphine (300 nM), 
55%; and normorphine (1 ~M), 79%. 
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Figure 23. Effect of normorphine on e.j.p. during superfusion with 
low calcium sqlution. This tissue had been bathed in Krebs solution 
containing.calcium (1.27 mM) for 3 h previous to time zero. Four 
concentrations of normorphine were tested on the e.j.p. in this cell, 
which was particularly sensitive to its action. Although normorphine 
(30 nM) had no effect, normorphine (100 ~M) depressed the e.j.p. by 
34%, normorphine (300 ru~) depressed it by 62% and normorphine (1 ~M) 
depressed it by 83%. The impalement ended before the effect of the 
final applicatio~ of normorphine had completely washed out. 
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in Figure 24. Values obtained in high, normal or low calcium solutions 
were compared at four concentrations of normorphine (100 nM, 300 nM, 
1 ~M and 3 ~M) using one-way analysis of variance. There was a signi-
ficant relationship between the effectiveness of normorphine and the 
calcium ion concentration at only one of these concentrations (300 nM: 
p = 0.02). This was due to a difference between the effectiveness of 
this concentration of normorphine in control vs. low calcium solution 
(Figure 24). The EC50 for normorphine was 270 nM in low calcium 
solution (1.27 mM), 370 nM in normal calcium solution (2.54 mM) and 
410 nM in high calcium solution (5.08 mM) as estimated from the 
composite dose-response curves (Figure 24). 
3.82 Stimulus strength not adjusted 
The effect of normorphine (1 ~M) in both normal and low calcium 
solutions was tested on the same cell. The stimulus strength was not 
changed when the calcium ion concentration was changed (Figure 25). 
Normorphine (1 ~M) depressed the e.j.p. by 74 ± 3.1% in normal calcium 
and by 75 + 4.8% in low calcium, in the five cells on which it was 
tested in this manner (Table 5). 
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Figure 24. Normorphine dose-response curves for depression of e.j.p. 
in tissues maintained in different calcium ion concentrations. These 
dose-response curves were constructed using results from vasa main-
tained in Krebs solutions containing high (5.08 mM), normal (2.54 mM) 
or low (1.27 mM) calcium ion concentrations. Bars represent + s.e. 
mean. Results from 52 cells (23 tissues). 
....... 
0 
o--
-
w 
0 
:::> 
1-
_J 
11.. 
2 
<( 
a: 
. 
..., 
w 
LL 
0 
z 
0 
(j} 
(j} 
w 
0::: 
11.. 
w 
0 
100 
80 
60 
40 
eCONTROL 
Oca++(1.27mM) 
0 Ca++(5.08mM) 
/ 
~~/------~----~------~----~ 
0.03 0.1 0.3 1 3 
NORMORPHINE (,U.M) 
136 
137 
Figure 25. Effect of halving the calcium ion concentration on depres-
sion of e.j.p~ by normorphine: same cell and same stimulation para-
meters. COntinuous record of e.j.p. amplitude during the impalement 
of a single cell. Stimulation strength was constant throughout the 
recording. During the time interval indicated by the open bar, the 
calcium ion concentration of the superfusing solution was reduced from 
2.54 mM to 1.27 mM. In this cell, normorphine (1 ~M) decreased e.j.p. 
amplitude by 84% in normal calcium solution and by 64% in the solution 
with reduced calc~um concentration. 
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Table 5. Effect of normorphine (1 ~M) on e.j.p. in normal and low 
calcium: same cell. Normorphine (1 ~) was tested on five cells 
bathed first in solutions with normal calcium (2.54 ru~), then in 
solutions with low calcium (1.27 mM). Stimulation parameters were 
constant. There was no difference between the mean depression of the 
e.j.p. by normorphine (1 ~) in normal and low calcium (Student's t 
test). 
Calcium (2.54 mM) Calcium (1.27 mM) 
E.j •P. amp. Depression of E.j .p. amp. Depression of 
Cell II (mV) e.j .p. (%) (mV) e.j .p. (%) 
7259-3 25 74 14 85 
8019-5 22 68 8 67 
8149-5 29 85 6 64 
10169-4 44 68 12 71 
10179-1 36 77 10 88 
X+ s.e.m. 31 + 4.0 mV 74 + 3.1% 10 + 1.4 mV 75 + 4.8% 
4. DISCUSSION 
4.1 E.j.p. amplitude as a measure of transmitter release 
Increasing the strength of stimulation of the intramural nerves 
of the mouse vas deferens will increase the number of nerve fibers that 
are activated and hence increase the amount of transmitter released 
into the junctional clefts in the vicinity of a single smooth muscle 
cell. The amplitude of the e.j.p. increases with strength of stimula-
tion, and hence it can be concluded that e.j.p. amplitude is a quanti-
tative estimate of transmitter release. Other aspects of e.j.p. 
configuration also vary with stimulus strength, such as the rate of 
rise of the e.j.p. (in V/s) and the area under the depolarization 
curve. Why was peak amplitude measured in the present experiments, and 
not these latter characteristics? 
The rate of rise of the e.j.p. increases with stimulus strength, 
and hence with the quantity of transmitter that interacts with the 
postsynaptic membrane. But measurements of peak amplitude are easier 
and more accurate. Small errors in measurements of amplitude as a 
function of time would produce large changes in the calculated rate of 
rise, whereas measurements of e.j.p. amplitude in the present study 
were accurate within+ 0.5 mV. Furthermore, the rate of rise of the 
e.j.p. in a particular cell which has been produced by a fixed amount 
of transmitter is dependent on the distribution of transmitter release 
sites in the vicinity. Release directly onto the impaled cell would 
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result in a fast rate of rise whereas release onto neighboring or more 
distant cells would result in a decreased depolarization rate. 
The area under the depolarization is influenced by the rise time, 
peak amplitude and decay time of the e.j.p. The ionic currents, and 
hence the conductance changes which produce the e.j.p., have not yet 
been measured; therefore the duration of transmitter action is not 
known. In the few smooth muscle cells of the mouse vas deferens in 
which conductance increases are observed in connection with transmitter 
action, these increases occur during the early portion of the e.j.p. 
(Holman, 1970). Thus the duration of the e.j.p. most likely does not 
reflect continued action of transmitter on the smooth muscle membrane. 
The falling phase of the e.j.p. probably is determined by the passive 
electrical properties of the smooth muscle membrane, as postulated by 
Bywater & Taylor (1980). They found that the time constant of decay of 
the evoked e.j.p. in the guinea-pig vas deferens was closely similar to 
the time constant of the smooth muscle membrane in this tissue. Since 
the final configuration of the e.j.p. is dependent on postsynaptic 
membrane properties as well as presynaptic events (transmitter release), 
the area under.the depolarization curve was not used as a quantitative 
measure of transmitter release. 
An increase in the amplitude of the e.j.p. results from the 
action of increasing quantities of transmitter. The transmitter pro-
duces the potential change by increasing the ionic conductance of the 
smooth muscle membrane, but the potential change is not linearly re-
lated to the conductance change (Martin, 1955). This non-linear 
relationship occurs because as the membrane becomes depolarized and 
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its potential approaches the equilibrium potential of the transmitter, 
the ionic driving force becomes less. Thus, at the height of the 
e.j .p., a given quantity of transmitter will produce a smaller poten-
tial change than would the same amount of transmitter applied to a 
resting membrane. To account for the non-linear relationship between 
transmitter action (conductance change) and e.j.p. amplitude (potential 
change), the following correction factor may be applied (Martin, 1955): 
v' = v (1 - ~)-l 
v 
0 
where v' =corrected e.j .p., v =measured e.j.p. amplitude, and 
V
0 
= VE- Vm (VE =equilibrium potential for e.j.p. and Vm =resting 
membrane potential). The corrected value of the e.j.p. (v') would be 
an estimate of "transmitter release" and hence would have no units. 
Any estimate produced by this method would be inaccurate because the 
noradrenaline equilibrium potential (VE) is not known (see Introduc-
tion, p. 48-49). Also, the actual value of the resting membrane 
potential (V ) is difficult to measure accurately because microelectrode 
m 
impalement of cells probably results in some degree of damage. If, 
however, an equ;librium potential of 0 mV and a resting membrane poten-
tial of -62 mV (see Results, p. 65) are assumed, then e.j.p. amplitudes 
can be corrected for non-linear summation as shown in Table 6. It is 
obvious that the greater the amplitude of the e.j.p., the less accurate-
ly does the potential change of the membrane reflect the quantity of 
transmitter released in the vicinity of that membrane. In most of the 
present experiments, the effectiveness of opiate agonists was tested on 
e.j .ps of approximately the same amplitude. In a few experiments, such 
Table 6. Correction of e.j.p. amplitude to account for non-linear 
summation. *v' = v v -1 (1 - v) (see text). Assumptions: v = 
m 
0 
-62 mV; VE = 0 mV, 
E .j .p. amplitude Corrected e .j. p. 
(mV) Recorded "Transmitter release" 
5 5 
10 12 
15 20 
20 30 
25 42 
30 58 
35 80 
40 114 
45 167 
50 250 
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as effect of stimulus strength on potency of normorphine and in some 
low calcium experiments, the effect of normorphine is assessed on 
e.j.ps of different amplitudes. The implications of non-linear summa-
tion will be discussed in relation to the results of these studies. 
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4.2 Depression of e.j .p. by opiates and opioid peptides 
Normorphine decreased the amplitude of the evoked ~.j.p. in the 
isolated vas deferens of the mouse, an action that was reversed by 
naloxone. This confirms the observations of Henderson & North (1976). 
The EC50 for normorphine in the present study (560 nM) was similar to 
the value obtained by those authors (430 nM), despite the fact that 
different strains of mice were used in the two studies. The effect of 
normorphine on the e.j.p. is likely to be the result of a decrease in 
the amount o7 transmitter released from the adrenergic varicosities in 
response to nerve stimulation (see Introduction). 
DAEA is an enkephalin analog that is resistant to enzymatic 
destruction (Pert, Bowie, Fong & Chang, 1976) and it acts primarily on 
~ receptors (Shaw, Turnbull, Dutta, Gormley, Hayward & Stacey, 1978). 
It also depressed the e.j.p., and was more potent in this action than 
normorphine, with an EC50 of 50 nM. Such an effect on the e.j.p. of an 
opioid peptide had previously been demonstrated for Met5-enkephalin 
(Waterfield et al., 1977). 
A second enkephalin analog, DADL, ~as also tested on the e.j.p. 
This opioid peptide is a potent and specific agonist at the 8 receptor 
(Chang & Cuatrecasas, 1979). Neuro-effector transmission in the mouse 
vas deferens was extremely sensitive to the depressant action of this 
peptide; the Ec50 for the depression of e.j.p. amplitude by DADL was 
500 pM. DADL was thus about 1,000 times more potent in this action 
than normorphine, a result which is consistent with the preponderance 
of a-type opiate receptors in the mouse vas deferens (Lord~ al., 
1977). It is assumed that the decrease in e.j.p. amplitude in the 
presence of the opioid peptides results from a depression of trans-
mitter release by these substances, as is true for normorphine 
(Henderson & North, 1976). 
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4.3 Effect of control e.j.p. amplitude and stimulus strength on the 
potency of normorphine 
The calculated percentage inhibition of e.j.p. amplitude by nor-
morphine was not related to the control amplitude of the e.j.p., be-
cause normorphine was as effective on e.j.ps of initially large ampli-
tude (35 mV) as on e.j.ps of initially smaller amplitude (10 mV) 
(Table 1). Any change in the effectiveness of normorphine (1 ~M) as a 
function of e.j.p. amplitude may not be evident because this concentra-
tion falls an the less sensitive (lower slope) portion of the dose-
response curve (Figure 3). This caveat does not apply for the lower 
concentrations of normorphine (especially 300 nM), although the 
effectiveness of these lower concentrations on e.j.p. amplitude is more 
variable from cell to cell (note standard deviations in Figure 3). In 
a few experiments, normorphine (100 nM or 300 nM) was tested on a 
large amplitude e.j.p. and a small amplitude e.j.p. of the same cell. 
Depending on the cell, normorphine was more effective, equally effective 
or less effective on the larger amplitude e.j.p. as compared to the 
smaller amplitude e.j.p. 
More nerve fibers must be excited in order to elicit an e.j.p. 
of larger amplitude (35 mV vs. 10 mV). The present results indicate 
that, at least for the nerve fibers with thresholds for excitation in 
a limited range of stimulus strengths, the sensitivity to normorphine 
must be similar. In all experiments the stimulus strength used to 
evoke an e.j.p. was submaximal; in most cells even the large amplitude 
(30-40 mV) e.j .ps did not give rise to action potentials. If the 
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potency of normorphine were measured on e.j.ps elicited by supramaximal 
stimulation, which usually are accompanied by action potentials and 
muscle contractions, and compared to its potency on submaximal e.j.ps, 
differences might very well have been found. Hughes et al. (1975a) 
measured the effect of normorphine on the nerve-evoked muscle contrac-
tions of the mouse vas deferens. They observed that normorphine was 
more effective on vasa stimulated with submaximal current strengths 
(Ec50 = 120 nM) compared to its efficacy on vasa stimulated with just 
supramaximal stimuli (Ec50 = 440 nM). Submaximal vs. supramaximal 
e.j.ps were not compared in the present study because only submaximal 
stimulation strengths were used in all experiments. 
If the amplitude of the e.j.p. is corrected using Martin's non-
linear summation formula so that the e.j.p. reflects "transmitter 
release" (Table 6), then the effectiveness of normorphine is apparently 
greater for large amplitude e.j.ps. For example, normorphine (300 nM) 
decreases the amplitude of 35 mV e.j.ps by an average of 39%, and 
decreases the amplitude of 10-11 mV e.j.ps by 46% (Table 1). The 
percentage depression of the "transmitter release" than these e.j.ps 
represent is 60% for high release and 48% for low release. The calcu-
lations were also made for e.j.ps depressed by normorphine (100 nM and 
1 ~M), and the results are similar. One possible explanation for the 
apparent greater effectiveness of normorphine on high levels of trans-
mitter release may be related to the geometry of release in the vas 
deferens. For large amplitude e.j.ps, more nerve fibers close to the 
impaled cell are likely to be excited, because the stimulus strength 
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has increased. An inhibitory effect of normorphine on transmitter 
release in the vicinity of a given cell would be more likely to result 
in a measurable decrease in e.j.p. amplitude than would inhibition of 
transmitter release at more distant sites. Transmitter that is re-
leased directly onto or near a cell makes a larger contribution to the 
amplitude of the e.j.p. than does transmitter released onto distant 
cells. 
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4.4 Prolonged exposure to morphine in vivo 
Intracellular recordings were made from smooth muscle cells of 
vasa taken either from naive mice or from mice pretreated with mor-
phine. The effects of opiates on neurotransmission in these vasa were 
compared. The three main questions addressed by this study were as 
follows. Does chronic morphine pretreatment lead to changes in the 
resting properties of the smooth muscle cells of the mouse vas 
deferens? Does tolerance develop to the inhibitory action of morphine 
at this neuio-effector junction? Can the administration of naloxone 
in vitro to a vas deferens exposed to morphine in vivo lead to changes 
in neuro-effector transmission which are an indication of "dependence"? 
These aspects will be discussed in turn. 
4.41 Resting membrane properties of the smooth muscle cells 
Opiates depress transmitter release in the mouse vas deferens 
in vitro (see above). Prolonged exposure to high concentrations of 
morphine in vivo may effectively interrupt neuro-effector transmission 
in the vas deferens so as to produce a pharmacological denervation. If 
excitable cells are chronically deprived of their normal physiological 
stimuli they become more sensitive to excitatory substances. This 
phenomenon in smooth muscle is postjunctional supersensitivity 
(Fleming, Urquilla, Taylor & Westfall, 1975). In the guinea-pig vas 
deferens, postjunctional supersensitivity produced by surgical dener-
vation is accompanied by a depolarization of the smooth muscle cells 
(Fleming & Westfall, 1975; Fleming~ al., 1975). Morphine pretreat-
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ment of mice did not alter the resting membrane potentials of single 
smooth muscle cells of their vasa deferentia. Presumably, during 
chronic exposure to morphine in vivo, neuro-effector transmission is 
more or less restored to normal due to the development of tolerance to 
the initial depressant effect of morphine on transmitter release (see 
below). Under these conditions, postjunctional supersensitivity would 
not develop. Another possibility is that postjunctional supersensi-
tivity in the mouse vas deferens is not accompanied by a change in the 
resting membrane potential of the smooth muscle cells. This is true 
for the smooth muscle cells of the supersensitive rat vas deferens 
(Goto, Westfall & Fleming, 1978). This is not likely because an in-
creased sensitivity to transmitter did not develop in vasa from 
morphine-pretreated mice (see below). 
Most of the experimental evidence suggests that noradrenaline is 
the transmitter released from the sympathetic nerve varicosities in the 
mouse vas deferens, and that the noradrenaline so released mediates the 
contractile response of the muscle to stimulation of the intramural 
nerves (see Introduction). Because surgical denervation leads to 
supersensitivity of smooth muscle to noradrenaline.and other substances 
(see Fleming et al., 1975), the effect of chronic morphine treatment on 
the response of the smooth muscle cells of the mouse vas deferens to 
exogenous noradrenaline was examined. There was no change in the sen-
sitivity of the muscle cells to noradrenaline after chronic morphine 
treatment. Rae, Neto & de Moraes (1977) reported that long-term treat-
ment of mice with morphine does lead to a supersensitivity of their 
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vasa deferentia to noradrenaline. The differences between the results 
of these investigators and the results of the present experiments may 
be related to differences in the schedule of morphine administration. 
Rae et al. administered morphine for 10 days, whereas mice were treated 
--
for 3 days in the present study. Perhaps any changes in muscle sensi-
tivity related to prolonged morphine treatment have not developed 
within 3 days (see below). Also, injection of animals twice a day 
(Rae et al.) as compared to 3 times a day (present study) may result in 
longer periods of relative withdrawal from morphine. Supersensitivity 
is a common finding in withdrawal from morphine both in vivo (Pollock, 
Muir, MacDonald & Henderson, 1972) and in vitro (North & Karras, 1978a). 
The noradrenaline EC50 for producing a contractile response of 
the vas deferens in vitro was not different in vasa from mice adminis-
tered morphine for 3 days as compared to vasa from naive mice. There 
was, however, a tendency for vasa from morphine-pretreated mice to 
respond to the higher concentrations of noradrenaline with larger 
increases in tension (Figure 15). A supersensitivity of smooth muscle 
which is characterized by an increased maximum response to an agonist, 
without an associated leftward shift of the dose-response curve to that 
agonist, has been observed under conditions in which blood cortico-
steroid levels are elevated. Such conditions include: morphine with-
drawal, thyroidectomy, injection of a single dose of reserpine, or 
chronic administration of corticosterone (Gibson & Pollock, 1975). The 
stress of daily multiple injections of a drug could also result in 
elevated levels of plasma glucocorticoids. Perhaps administration of 
morphine to mice for a longer time in the present experiments would 
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have resulted in a statistically significant increase in the maximum 
response of the vas deferens to noradrenaline, an increase which may be 
only partially developed after three days. 
Most importantly, significant tolerance to the effect of opiates 
on transmitter release (see below) can be demonstrated in vasa which 
are not supersensitive, or have only a marginally increased sensitivity, 
to the transmitter noradrenaline. Thus supersensitivity of the post-
synaptic effector cell to transmitter does not account for tolerance to 
morphine in this tissue. 
4.42 Tolerance to the effect of normorphine 
The EC50 for the depression by normorphine of e.j.ps was twelve 
times higher in vasa from morphine-pretreated mice than the Ec50 in 
vasa from naive mice (Figure 12). Transmitter release in vasa from 
morphine-pretreated mice was thus relatively insensitive to normor-
phine. The isolated tissue may, therefore, be said to be tolerant to 
the inhibitory action of normorphine on the nerve terminals. Cox 
(1978) reported a four-fold degree of tolerance to the inhibitory 
action of morphine on the nerve-mediated contractions of vasa. These 
vasa were removed from mice which had been implanted with morphine 
pellets for five days. A previous study of the effect of opiates on 
the contractions of vasa from pellet-implanted mice (Waterfield, Hughes 
& Kosterlitz, 1976) also did not report the high degree of tolerance 
seen in the present study. The experimental procedures of these 
studies and the present one differ in two major respects. First, Cox 
(1978) and Waterfield~ al. (1976) used pellet implantation, whereas 
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multiple injections (8 hour intervals) was the method of morphine pre-
treatment in the present study. Second, in the other studies the con-
tractions of the smooth muscle in response to supramaximal stimulation 
of the nerves were measured. In the present study the effectiveness of 
normorphine was assessed on the amplitude of the e.j.p.; the e.j.p. was 
elicited by submaximal stimulation of the intramural nerves. 
The pattern of exposure of the vas deferens to morphine would 
differ in pellet-implanted mice as opposed to mice receiving multiple 
injections. Vasa in pellet-implanted mice would be exposed to lower 
but less variable concentrations of morphine. In contrast, blood 
levels of morphine would markedly vary in the mice receiving intra-
peritoneal injections. The plasma concentration of morphine was mea-
sured in mice that were treated with the same morphine injection 
schedule as the animals whose vasa were used for intracellular record-
ings. Two hours after the last (ninth) morphine injection of 140 mg/kg 
(the time when the mouse would have been killed and the vasa removed 
for experimentation), the plasma morphine concentration averaged 6.7 ~M 
(range 3.2 to 13.8 ~M; n = 4). Eight hours after the final injection 
(the time for the next injection, if the treatment schedule would have 
continued), the morphine concentration in the plasma averaged 900 nM 
(range 250 nM- 1.5 ~M; n = 6) (Wainer, personal communication). 
Normorphine (1 ~M) did not depress the e.j.p. in vasa of morphine-
pretreated mice (Figure 10). Thus with this injection schedule, neuro-
effector transmission would be periodically restored to normal (when 
the blood level approached 900 nM) and would be intermittently depressed 
(when the blood level approached 7 ~M). This assumes that the concen-
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tration of morphine in the vicinity of the opiate receptors in the vas 
deferens is similar to the plasma concentration. This schedule of 
exposure to morphine may be more favorable for the development of 
tolerance in the mouse vas deferens, as opposed to a schedule of 
exposure which results in steadily declining blood concentrations (such 
as pellet implantation). 
When the effect of morphine is studied on the contractions of 
the smooth muscle of the vas deferens, supramaximal stimulation of the 
intramural nerves is used to elicit these contractions. But the po-
tency of normorphine in inhibiting the muscle contractions is greater 
if submaximal stimulation currents are used (Hughes et al., 1975a). 
E.j .ps were elicited by submaximal stimulation strengths, but the 
effect of normorphine on the e.j.p. was independent of the e.j.p. 
amplitude, and of the stimulus strength used to evoke it (Table 1). 
Furthermore, in the present study the potency of normorphine on 
muscle contractions evoked by supramaximal stimulus strengths was com-
pared to its potency in inhibiting the amplitude of e.j.ps elicited by 
submaximal stimuli, in different mice of the same strain. In vasa from 
naive mice of .the CF-1 strain, normorphine was as effective or more 
effective in inhibiting the contractile responses of the muscle (EC50 
values 165-400 nM) in the vasa tested in this manner, as it was in 
depressing the e.j.p. (Ec50 values 270-890 nM) in other vasa. A 
similar relationship held for vasa from morphine-pretreated mice. In 
these tissues, the Ec50 values for normorphine for inhibition of the 
nerve-evoked muscle contraction (1.6-7.8 ~M) were similar to the values 
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for the inhibition of the e.j .p. (3-30 ~M). For these reasons, it is 
unlikely that the high degree of tolerance (twelve-fold) observed in 
the present study as opposed to previous studies is related to the 
method used for assessing the potency of opiates (e.j.p. amplitude) or 
to the use of submaximal stimulation strengths to elicit transmitter 
release. 
Is it possible that the shift to the right of the dose-response 
curve for the effect of normorphine on the e.j .p. in vasa from mor-
phine-pretreated mice was a consequence not of in vivo exposure to 
morphine, but of in vitro exposure to normorphine (300 nM)? To inves-
tigate this possibility, some vasa from naive mice were maintained in 
Krebs solution containing normorphine (300 nM) for 1-5 hours, and the 
effect of higher concentrations of normorphine (1 and 3 ~M) were 
tested. Normorphine (1 and 3 ~M) still depressed the e.j.p. Although 
in these vasa normorphine (1 ~M) was significantly less effective than 
in vasa not exposed to opiate drug in vitro, this concentration of nor-
morphine never depressed the e.j.p. in vasa from morphine-pretreated 
mice. The effect of normorphine (3 ~M) was not changed by exposure of 
the tissue to normorphine in vitro, whereas it was significantly de-
creased by exposure of the tissue to morphine in vivo. Thus the expo-
sure of the vas deferens to high concentrations of morphine in vivo, 
and not its maintenance in normorphine (300 nM) in vitro, produced the 
tolerance to the effect of normorphine on transmitter release. 
At the time the morphine-pretreated mice were killed and their 
vasa removed for experimentation, blood levels of morphine probably 
were in the ~M range (see above). However, the vasa were maintained 
157 
in vitro in Krebs solution containing a lower concentration of nor-
morphine (300 nM). The tissues would therefore be in a state of partial 
withdrawal during subsequent experimentation. Perhaps the degree of 
tolerance to morphine attained in vivo by the vas deferens is even 
greater than was measured in vitro, after the tissue had been partially 
withdrawn. Normorphine at the concentration used in the present study 
(300 nM) was able to prevent complete withdrawal of the tissue, because 
tissues maintained under these conditions were still highly tolerant to 
normorphine (Figure 12) and responsive to naloxone (Figure 14). 
Morphine pretreatment of mice produced a decreased sensitivity to 
normorphine of neuro-effector transmission in the vas deferens. Did 
this treatment also produce tolerance to other substances which de-
crease transmitter release at this site? Adenosine inhibits both 
neurally-evoked contractions of the muscle and [ 3H]-noradrenaline re-
lease from the isolated vas deferens of the rat. Furthermore, the 
responses to exogenous noradrenaline are not affected by adenosine; 
this indicates a prejunctional site of action (Clanachan, Johns & 
Paton, 1977). The effect of adenosine on the e.j.p. in the mouse vas 
deferens was investigated so as to determine whether prolonged expo-
sure to morphine brought about changes in the sensitivity of the 
intramural nerves to adenosine as well as to morphine. Adenosine 
depressed the e.j.p., but its ability to do so was not changed by 
morphine pretreatment. That is, morphine pretreatment led to tolerance 
to the action of morphine without cross-tolerance to adenosine. 
Similarly, implanting mice with morphine pellets for 3 days does not 
alter the presynaptic inhibitory effect of the aadrenergic agonist 
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clonidine (Robson, Gillan, Waterfield & Kosterlitz, 1978). 
4.43 Manifestation of "dependence" - effect of naloxone 
Naloxone did not change the resting membrane potential of the 
smooth muscle cells of vasa from morphine-pretreated mice. However, 
naloxone did cause a large increase in the amplitude of the evoked 
e.j.p. in those vasa. Was this simply a reversal of the ongoing 
depression of the e.j.p. by the normorphine present in the bathing 
solution? Two factors suggest not. First, the vasa should have been 
tolerant to 'the normorphine concentration (300 nM) present in the bath 
fluid because a higher concentration of normorphine (1 ~M) did not 
depress the amplitude of the e.j .p. Second, the increase in e.j .p. 
amplitude observed upon administration of naloxone to the vasa from 
morphine-pretreated mice was marked (3.5 to 7-fold). The average 
increase in amplitude was 360 + 37%. When naloxone was used to reverse 
the depression caused by a short-lasting (10 min) application of nor-
morphine (300 nM) to vasa from naive mice, the e.j.p. amplitude re-
turned only to its control level before application of drugs. This 
represented an increase in e.j.p. amplitude of 64 ± 11%. 
It is possible that the exposure to normorphine (300 nM) in vitro 
was the cause of the increased response to naloxone in vasa from 
morphine-pretreated mice. Therefore naloxone was also tested on 
control vasa which were maintained for 5-8 hours in Krebs solution con-
taining normorphine (300 nM). Cells from these preparations responded 
to naloxone (300 nM) with an increase in e.j.p. amplitude of 184 + 21%. 
There was a significant change in the effectiveness of naloxone on 
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e.j .p. amplitude as the duration of exposure to opiate increased, if 
the responses of naive vasa exposed to opiate for 10 minutes, the 
responses of naive vasa maintained in opiate for 1-5 hours, and the 
responses of vasa from morphine-pretreated animals are compared (one-
way analysis of variance: p<O.Ol). There was thus a trend toward 
increased responsiveness to naloxone as the duration of exposure to 
opiate drug increased. 
An increase in the effectiveness of naloxone as a function of 
duration of exposure to opiates has been observed in whole animal 
studies, as well as in other in vitro preparations. The dose-response 
curve for morphine for producing antinociception in the tail-flick 
test in mice was shifted to the right if naloxone (160 ~g/kg) was 
administered concurrently with the test dose of morphine. The dose-
response curve was shifted to a greater extent in mice that have been 
pretreated with morphine (30 mg/kg) 3 hours before testing. The mor-
phine Ec50 was not changed by this pretreatment (Tulunay & Takemori, 
1974a). Furthermore, in animals rendered tolerant to morphine by 
multiple injections or by implantation of morphine pellets, naloxone 
(160 pg/kg) also increased the morphine Ec50 , and the sensitivity to 
this effect of naloxone was greater than in animals that have been 
acutely treated with morphine. The increase in the efficacy of nalo-
xone observed after morphine treatment appeared before tolerance to the 
antinociceptive activity of morphine developed, and the efficacy of 
naloxone increased faster than the development of tolerance (Tulunay & 
Takemori, 1974b). In another series of experiments, slices of corpus 
striatum were incubated in Krebs solution containing [3H]-morphine, and 
the overflow of label during subsequent superfusion with drug-free 
solutions was measured. The addition of naloxone (1-100 pM) to the 
superfusate resulted in a dose-related increase in the overflow of 
label. The sensitivity to this effect of naloxone was increased in 
slices from mice given morphine pretreatment, either by a single 
injection of morphine (100 mg/kg) 3 hours before the animal was 
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killed for experimentation, or by pellet implantation 3 days before the 
experiment. The time course for the development of the enhanced 
potency of naloxone in striatal slices paralleled the time course for 
the development of tolerance in the whole animal, as assessed by the 
tail-flick method (Kitano & Takemori, 1979). 
A time-dependent increase in naloxone sensitivity also occurs in 
the guinea-pig ileum. In this tissue, a naloxone-precipitated muscle 
contracture is the manifestation of withdrawal from opiate drugs (see 
North & Karras, 1978a). Naloxone can induce a muscle contracture in a 
tissue removed from a naive guinea-pig if this tissue is maintained in 
Krebs solution containing normorphine (200 nM). The degree of tension 
developed by the muscle in response to naloxone increases as time of 
exposure to normorphine increases. The effect of naloxone is much 
enhanced in tissues removed from morphine-dependent animals and main-
tained in morphine solution (Schulz & Herz, 1976). In the present 
experiments, the increase in e.j.p. amplitude caused by naloxone in 
vasa exposed to normorphine (300 nM) was also much greater if the 
tissue was removed from morphine-pretreated mice as distinct from 
naive mice. Large increases in e.j .p. amplitude were also observed in 
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tissues from morphine-pretreated mice if the superfusing solution was 
changed from one containing opiate (normorphine - 300 nM) to another 
that was drug-free. These increases were not as large or as consistent 
as those obtained by superfusion with naloxone. The large increase in 
e.j .p. amplitude elicited by naloxone in vasa from morphine-pretreated 
mice may be analogous to the muscle contracture in the guinea-pig 
ileum. The increase in sensitivity to naloxone of the nerve terminals 
in the mouse vas deferens may therefore represent "dependence" on mor-
phine in this tissue. 
Normorphine inhibits evoked but not spontaneous release of trans-
mitter from the sympathetic nerves in the mouse vas deferens: the 
amplitudes of evoked e.j.ps are depressed (Henderson & North, 1976) but 
the frequency and amplitudes of spontaneous e.j.ps are not modified 
(Henderson, 1976). In the present study naloxone did not cause a large 
increase in the spontaneous release of transmitter from the nerve 
terminals of vasa from morphine-pretreated mice. Such a massive 
release would have been observed either as a depolarization of the 
smooth muscle cells or as a burst of firing of spontaneous e.j.ps: 
neither occurred. Thus, it is reasonable that naloxone-precipitated 
"withdrawal" in the mouse vas deferens is manifest as a dramatic in-
crease in evoked release of transmitter (amplitude of evoked e.j.p.) 
but not as a change in spontaneous transmitter release. 
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4.44 Conclusions 
The precise nature of the change in neuro-effector transmission 
in the mouse vas deferens caused by prolonged exposure to morphine in 
vivo is not known. Clearly, though, the change takes place in the 
nerve terminals which are sensitive to the action of morphine. These 
nerve terminals become tolerant to the depressant action of morphine on 
transmitter release. The postsynaptic cells which are not opiate-
sensitive did not exhibit changes in resting membrane potential or in 
sensitivity to transmitter. These findings do not support theories of 
opiate tolerance and dependence which invoke changes in postsynaptic 
sensitivity following blockade of transmitter release (Collier, 1968). 
It will be of interest to see if tolerance develops in the mouse 
vas deferens as a consequence of in vitro as well as in vivo exposure 
to opiates. The development of tolerance in vitro has been demon-
strated in the guinea-pig ileum (Hammond, Schneider & Collier, 1976; 
North & Karras, 1978b) and in explants of fetal mouse spinal cord in 
tissue culture (Crain, Crain, Finnigan & Simon, 1979). The degree of 
tolerance to the depressant action of opiates on transmitter release in 
the mouse vas deferens can be easily quantified by measuring changes in 
Ec50 values. This technique would thus be a sensitive way to assess 
the effectiveness of treatments purported to alter the development of 
opiate tolerance in other systems, such as protein synthesis inhibitors 
(see Smith, 1971), peptides (Walter, Ritzmann, Bhargava & Flexner, 
1979), cyclic nucleotides (Hammond~ al., 1976) and low incubation 
temperatures (Crain et al., 1979). 
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4.5 Cyclic AMP and inhibition of transmitter release by opiates 
The proposal that ~~ is involved in excitation-secretion 
coupling in nerve terminals has been examined at both somatic and auto-
nomic neuro-effector junctions. Cyclic AMP has also been considered as 
a mediator of the presynaptic alterations of transmitter release from 
sympathetic nerves induced by 8-adrenergic agonists, serotonin and, in 
the present study, opiates. 
4.51 Role of cAMP in transmitter release 
Calcium is required for the evoked release of transmitter from 
nerves, but is an increase in the intraterminal concentration of cAMP 
also a prerequisite? Can c~~ alter the amount of calcium entering 
nerve terminals in response to a depolarizing stimulus, or the effec-
tiveness of calcium in promoting transmitter release? Cyclic AMP, 
dbcAMP and IBMX potentiate the electrically-induced but not the spon-
taneous release of [ 3H]-dopamine from slices of rat neostriatum 
(Westfall, Kitay & Wahl, 1976). The role of cAMP in transmitter re-
lease has also been examined on peripheral nerves. In the isolated rat 
diaphragm-phrenic nerve preparation, dbcAMP and theophylline increase 
the amplitude of the end-plate potential by a prejunctional action on 
the cholinergic nerve terminal (Goldberg & Singer, 1969). Systemic 
administration of dbcAMP, theophylline or NaF (an activator of adenyl-
ate cyclase) induces spontaneous activity and increases the stimulus-
evoked response of single motor axons of cat soleus nerve in vivo 
(Dretchen, Standaert, Skirboll & Morganroth, 1976). A possible 
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mechanism for this effect is a facilitation by cAMP of calcium influx 
into the motor axons (Skirboll, Baizer & Dretchen, 1977; Skirboll, 
Standaert & Dretchen, 1979). 
Cyclic nucleotides and phosphodiesterase inhibitors also can 
enhance autonomic neurotransmission. In the isolated perfused spleen, 
the monobutyryl derivative of cAMP (mbcAMP) and the phosphodiesterase 
inhibitors IBMX, papaverine and RO 20-1724 enhance the nerve-evoked 
overflow of [3H]-noradrenaline and dopamine-S-hydroxylase (DSH) 
(Cubeddu, Barnes & Weiner, 1974 & 1975). The effect of the phospho-
diesterase inhibitors on evoked noradrenaline release from the spleen 
does not, however, correlate with their potencies in causing inhibition 
of splenic phosphodiesterase (Cubeddu et al., 1974; Stjarne, 1979). 
Also, a derivative of cGMP (8-bromo-cGMP) is as effective in this 
action as the cAMP analogs (Cubeddu ~ al., 1975). Wooten, Thoa, 
Kopin & Axelrod (1973) report an enhancement of the evoked release of 
[3H]-noradrenaline and DSH from the guinea-pig vas deferens by dbcAMP 
(100 ~M) or theophylline (1 mM). These results could not be repeated 
by another investigator (Stjarne, 1976). Differences in stimulation 
parameters and the difficulty of accurately measuring the small amount 
of DSH released from the vas deferens could account for the discrepancy 
(Stjarne, 1976 & 1979). Stjarne, Bartfai & Alberts (1979) saw an 
enhancement of nerve-evoked secretion of [3H]-noradrenaline from the 
guinea-pig vas deferens in the presence of another analog of cAMP 
(8-bromo-cAMP) and more specific inhibitors of phosphodiesterase (IBMX 
and SQ 20,006). None of these studies at either somatic or autonomic 
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nerve-muscle junctions offers conclusive evidence that cAMP is an 
essential intermiediate in excitation-secretion coupling. But the 
presence of cyclic nucleotide derivatives and phosphodiesterase inhibi-
tors, which may produce alterations in the concentration of cAMP in 
nerve terminals, appears to modify transmitter release at some sites 
under some experimental circumstances. 
In the present study, cAMP and dbcAMP depressed rather than 
enhanced e.j.p. amplitude in the mouse vas deferens. Because cAMP does 
not readily penetrate cell membranes, the effect of this substance 
probably is a result of interaction with adenosine receptors located 
extracellularly on the presynaptic nerve terminals (Clanachan et al., 
1977). Dibutyryl cAMP more readily crosses cell membranes and hence 
less would remain in the extracellular fluid to activate those recep-
tors. The relative potencies of adenosine, cAMP and dbcAMP for inhibi-
tion of e.j.p. amplitude in the mouse vas deferens (adenosine>cAMP> 
dbcAMP) match their relative potencies for action on adenosine recep-
tors in the guinea-pig ileum (Sawynok & Jhamandas, 1976). In the 
latter tissue these purine compounds reduce the output of acetylcholine 
in response to. electrical stimulation of the nerves (Takagi & 
Takayanagi, 1972). Because adenosine inhibits evoked noradrenaline 
release from the rat vas deferens (Clanachan et al., 1977) and the cat 
spleen (Mueller, Mosimann & Weiner, 1979), a similar action of com-
pounds acting on the adenosine receptors of the mouse vas deferens is 
assumed. 
The increase of e.j.p. amplitude by IBMX and SQ 20,006 in the 
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present study is likely to be a presynaptic action on the nerve termi-
nals because these compounds enhance the stimulation-evoked release of 
noradrenaline and DSH at other sympathetic junctions (see above). A 
postsynaptic sensitization of the smooth muscle membrane to transmitter 
is another possible action, which unfortunately could not be disproved. 
IBMX alone or combined with dbcAMP inhibited the contractile response 
of the smooth muscle of the mouse vas deferens to both noradrenaline 
and potassium ion, suggesting a direct interference with excitation-
contraction coupling. Postsynaptic actions of phosphodiesterase 
inhibitors have previously been observed with the pressor response of 
splenic vasculature (Cubeddu ~ al., 1974) and the contractile response 
of the guinea-pig vas deferens (Stjarne et al., 1979). 
Is the effect of IBMX on e.j.p. amplitude a result of inhibition 
of phosphodiesterase or is it caused by another action of this com-
pound? The structure of IBMX is that of a methylxanthine, and methyl-
xanthines such as theophylline increase the entry of calcium across 
cell membranes (Blinks, Olson, Jewell & Braveny, 1972), mobilize cal-
cium from intracellular storage sites (Johnson & Inesi, 1969) and 
potentiate calcium-dependent ionic currents, independent of an inhibi-
tion of phosphodiesterase (Smith, Weight & Lehne, 1979). Methyl-
xanthines also antagonize the actions of adenosine (Sattin & Rall, 
1970) and prostaglandins (Horrobin, Manku, Franks & Hamet, 1977). Al-
though the effect of IBMX in the mouse vas deferens could be caused by 
any of these actions, it is more likely to be the result of inhibition 
of phosphodiesterase for several reasons. The non-xanthine phospho-
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diesterase inhibitor SQ 20,006 had the same effect. Also, IBMX and 
dbcAMP applied simultaneously were more effective than IBMX alone. In 
one cell dbcAMP was applied after the preparation had been superfused 
with IBMX for several minutes: -in this cell dbcAMP increased e.j.p. 
amplitude. In the absence of phosphodiesterase inhibition the increase 
in cAMP caused by hydrolysis of intracellular dbcfu~ may be prevented 
by endogenous phosphodiesterase. Phosphodiesterase inhibitors (IBMX or 
SQ 20,006) would protect the released cAMP from metabolism. Thus the 
effects of IBMX and dbcAMP would be complementary. Lastly, IBMX en-
hances transmitter release in another preparation (molluscan neurons), 
an action which can be mimicked by intracellular injection of cAMP 
(Klein & Kandel, 1978). 
4.52 Cyclic AMP and presynaptic modulation of transmitter release 
The enhancement of transmitter release from sympathetic nerve 
terminals by e-adrenergic agonists may be mediated by an increase in 
the intraterminal concentration of cAMP. Celuch, Dubocovich & Langer 
(1978) report that both e-adrenergic agonists and phosphodiesterase 
3 inhibitors (papaverine and IBMX) enhance the overflow of [ H]-noradren-
aline induced by nerve stimulation in the perfused cat spleen. Pro-
pranolol reduces the effect of the phosphodiesterase inhibitors, as 
well as the effect of the S-adrenergic agonists. This suggests that 
the phosphodiesterase inhibitors may be enhancing the action of endo-
genous noradrenaline which, after its release, is interacting with S 
receptors on the nerve terminals. The S-adrenergic agonists isoprena-
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line and terbutaline also enhance the potassium-evoked release of nor-
adrenaline from the pineal gland, an action shared by dbcAMP (Pelayo, 
Dubocovich & Langer, 1978). Also, a selective inhibitor of cAMP-
specific phosphodiesterase enhances noradrenaline release in pineal 
glands in which the presynaptic a-adrenergic receptors are blocked by 
yohimbine. The action of another presynaptic modulator, serotonin, may 
also be mediated by cAMP at a particular ganglionic synapse of Aplysia. 
Presynaptic facilitation of transmitter release at this synapse by a 
sensitizing stimulus in a sensory nerve pathway is simulated by extra-
cellular application of serotonin or dbcAMP or by intracellular injec-
tion of c.~ (Kandel, Brunelli, Byrne & Castellucci, 1976). 
The involvement of cAMP in the inhibition by opiates of trans-
mitter release from axon varicosities of the mouse vas deferens was 
tested in the present study. Caution is warranted in the interpreta-
tion of results from vasa exposed to cyclic nucleotides (cAMP or 
dbcAMP) because these substances may have postsynaptic effects on the 
smooth muscle membrane, perhaps altering the sensitivity to the trans-
mitter noradrenaline. Postsynaptic effects of the nucleotides on the 
response to noradrenaline could not be tested because, like IBMX, these 
substances inhibit excitation-contraction coupling in smooth muscle. 
Exposure of the vas deferens to cAMP (1 ~~),which depressed the ampli-
tude of the e.j.p., did not alter the potency of normorphine in causing 
a further depression of transmitter release. These compounds are 
acting at different receptors, cAMP at the adenosine receptor (see 
above) and normorphine at the opiate receptor. Substances which bind 
to these receptors are unlikely to have a common mode of action because 
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tolerance to the action of opiates is not accompanied by tolerance to 
the action of adenosine (see above). This result does not support the 
conclusions of studies which purport to show antagonism of the action 
of morphine by administration of cAMP (Ho ~ al., 1973). The effect of 
normorphine also was unaltered by the drug combination IBMX + dbcAMP. 
The increase in transmitter release in the presence of this combination 
may reflect an increase in the intraterminal levels of cAMP (see 
above). If this is the case, then the potency of the narcotic does not 
depend on the concentration of cAMP in the nerve terminals which bear 
the opiate receptors. Enkephalins are more potent than narcotics as 
inhibitors of transmitter release in the mouse vas deferens (Lord et 
al., 1977). The enkephalin analog DAEA was more potent than normor-
phine in depressing e.j.p. amplitude, but its effect was also not 
blocked by IBMX + dbcAMP in concentrations which produced an even 
greater enhancement of e.j.p. amplitude and, presumably, intraterminal 
cAMP concentrations. 
Neurotransmission in the mouse vas deferens is much more sensi-
tive to inhibition by a-type opiate agonists than by ~ agonists (Lord 
~ al., 1977). Furthermore, the most direct demonstration that opiates 
alter cAMP levels comes from studies of hybrid neuroblastoma x glioma 
cells grown in tissue culture, and the opiate receptors on these cells 
are almost exclusively of the a-type (Chang, Cooper, Hazum & 
Cuatrecasas, 1979). Thus it is possible that cAMP is involved only in 
the actions of opiates mediated by a receptors, and not the actions 
mediated by~ receptors. This is not likely because the depression of 
the e.j.p. by the specific 8 agonist DADL was not changed by IBMX + 
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dbcAMP. 
Is it possible that the acute effects of opiates are mediated by 
a decrease in neuronal cAMP concentrations, but other factors can 
account for the inability of cyclic nucleotides and IBMX to block the 
action of opiates in the mouse vas deferens? Firstly, are these sub-
stances (IBMX, dbcA}~) actually increasing the cAMP concentrations at 
the transmitter release sites in the axon varicosities? The evidence 
that they are is indirect because the anatomy of the vas deferens pre-
cludes the direct measurement of cAMP levels in the nerve terminals. 
The concentrations of IBMX used in the present study (50 ~M, 500 ~M) 
are probably high enough to inhibit cAMP phosphodiesterase because in 
other systems the IC50 for inhibition of cAMP phosphodiesterase by IBMX 
is approximately 5 ~M (Beavo, Rogers, Crofford, Hardman, Sutherland & 
Newman, 1970; Collier et al., 1976). Furthermore, similar concentra-
tions of IBMX do increase cAMP levels in other tissues (neuroblastoma 
cells: Hamprecht & Schultz, 1973; slices of anterior pituitary gland: 
Schofield & McPherson, 1974). Also, the effectiveness of the drug 
combination IBMX + dbcAMP in enhancing transmitter release in the mouse 
vas deferens (see above) suggests that these substances are directly or 
indirectly affecting the transmitter release sites in the varicosities. 
The action of opiates on transmitter release may result instead 
from alterations in cGMP levels in the varicosities. There is evidence 
that in the rat pineal gland the inhibition of the release of noradren-
aline by a-adrenergic agonists is mediated by an increase in the cGMP 
levels of noradrenergic nerve endings (Pelayo~ al., 1978). In this 
context it is of interest that withdrawal of a tolerant guinea-pig 
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ileum from morphine renders the preparation insensitive to clonidine, 
an a-adrenergic agonist that usually is a potent inhibitor of the 
evoked release of acetylcholine (Robson et al., 1978). Similarly, the 
ratio of cAMP to cGMP may be important in the actions of opiates, and 
not the absolute level of either one. IBMX inhibits hydrolysis of cGMP 
(Kakiuchi, Yamazaki, Teshima, Uenishi & Miyamoto, 1975) as well as 
hydrolysis of cAMP, and thus may not alter this ratio in the adrenergic 
nerves so as to block the action of morphine. Further experimentation 
is needed to confirm or refute this hypothesis that cGMP and not cAMP 
mediates the inhibition of transmitter release by opiates in the mouse 
vas deferens. 
Opiates inhibit transmitter release in the mouse vas deferens by 
a presynaptic action on the adrenergic nerves. Another major action of 
opiates is depression of the firing rate of single neurons. The com-
bined presence of IBMX + dbcAMP was unable to alter the acute inhibi-
tory action of morphine on the firing rate of single myenteric neurons 
of the guinea-pig ileum (Karras & North, 1979). The opiate-sensitive 
neurons of both the mouse vas deferens and the guinea-pig ileum are 
peripheral in location. The effect of"cAMP on the actions of opiates 
on central neurons in vivo has also been tested, and the results are in 
agreement with the results obtained using peripheral neurons. Thus, 
the depression by iontophoretically-applied morphine of the activity of 
lamina V cells in the spinal cord is unaffected by the simultaneous 
iontophoresis of IBMX or of dbcAMP (Duggan & Griersmith, 1979). 
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In the neuroblastoma x glioma hybrid cells, opiates acutely de-
crease cAMP concentrations, but prolonged exposure to opiates produces 
tolerance to this effect in that the cAMP concentrations return to 
normal despite the continuous presence of opiate drug (Sharma et al., 
1975b). It has been suggested (Karras & North, 1979; Collier, 1980) 
that cAMP is involved in the chronic but not the acute actions of 
opiates. There is evidence against the involvement of cAMP in the 
acute actions of opiates on transmitter release (present study) and 
on the firing rate of single neurons (Karras & North, 1979; Duggan & 
Griersmith, 1979). The involvement of cAMP in the long-term effects 
of morphine, that is, the development of tolerance and dependence, 
remains to be tested. 
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4.6 Calcium ion and inhibition of transmitter release by opiates 
4.61 Presynaptic modulation of transmitter release: role of calcium 
Transmitter release is a function of the concentration of calcium 
ion at release sites within nerve terminals. Therefore it has been 
proposed that substances which modulate transmitter release alter 
calcium availability or action at these sites. 
The release of noradrenaline from sympathetic nerve endings can 
be inhibited by a-adrenergic agonists, muscarinic agonists and prosta-
glandins (see reviews by Starke, 1977; Westfall, 1977). The effects 
of these substances on transmitter release have several features in 
common. First, only noradrenaline release that is dependent on the 
presence of extracellular calcium is inhibited. Release evoked by 
stimulation of nerves or by direct depolarization of nerve terminals 
with high concentrations of potassium is sensitive, whereas spontaneous 
or tyramine-induced release is insensitive. Second, the degree of 
inhibition by these substances appears to depend on the concentration 
of calcium ion in the extracellular fluid; high calcium decreases and 
low caJcium increases their effectiveness. Lastly, these substances 
are more potent at low as opposed to high frequencies of nerve stimula-
tion. The facilitation of transmitter release that occurs at high 
frequencies of stimulation has been explained by an increase in the 
amount of calcium available at the transmitter release sites (Younkin, 
1974). These findings are interpreted as evidence that calcium has a 
pivotal role in presynaptic inhibition. 
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The inhibition of transmitter release by opiates is also con-
sidered to be mediated by a decrease in calcium availability for 
similar reasons. Thus, in the mouse vas deferens morphine depresses 
the release of noradrenaline evoked by nerve stimulation (Henderson 
et al., 1972) or high potassium solutions (Sim & Henderson, personal 
communication), but not the spontaneous release of noradrenaline 
measured either biochemically (Hughes et al., 1975a) or electro-
physiologically (Henderson, 1976). Spontaneous transmitter release 
is not dependent on the extracellular calcium ion concentration 
(Hashimoto & Holman, 1967; Hubbard, Jones & Landau, 1968; Rubin, 1970). 
Also, the depression by morphine of the neurally-mediated contractions 
of the smooth muscle and of the release of noradrenaline from the 
adrenergic varicosities of the mouse vas deferens is frequency-
dependent; morphine is more potent at low than at high frequencies of 
nerve stimulation (Henderson & Hughes, 1976). At other sites of neuro-
transmission which are sensitive to opiates, the potency of the opiates 
appears to depend on the extracellular calcium ion concentration. For 
example, DAEA depresses the amplitude of e.p.s.ps evoked by pre-
ganglionic stimulation of prevertebral sympathetic ganglia, an effect 
that is more marked in low calcium (0.7 mM)-high magnesium (2 mM) 
solutions than in solutions containing higher concentrations of calcium 
ion (Konishi, Tsunoo & Otsuka, 1979). Also, opiates depress the 
negative slow waves recorded in fetal explants of mouse spinal cord 
during stimulation of the attached dorsal roots; this action is reduced 
in high calcium solutions (3-5 mM vs. 1 mM) (Crain, Crain, Peterson & 
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Simon, 1978). 
More direct evidence for modulation of calcium currents by sub-
stances that presynaptically alter transmitter release has been pro-
vided by studies of ganglion cells in vitro. The action potential of 
the soma of immature chick dorsal root ganglion cells has a calcium-
dependent plateau phase which is accentuated in high calcium solutions 
or in solutions containing barium (Dichter & Fischbach, 1977). The 
duration of this plateau phase is shortened by noradrenaline and sero-
tonin (Dunlap & Fischbach, 1979), as well as by the opioid peptide DAEA 
(Mudge, Leeman & Fischbach, 1979). This effect of DAEA on the ganglion 
cell bodies correlates with its inhibition of the release of substance 
P from the nerve terminals of these cells, although the postulate that 
the same mechanism is responsible for both effects is inference. It is 
unlikely that the membranes of a neuron's cell body and its axon ter-
minals are identical with respect to distribution, density and proper-
ties of ionic channels as well as susceptibility of those channels to 
external regulation. The presence of high calcium concentrations is 
required to demonstrate clearly the effect of the opioid peptide in 
these cells, whereas transmitter release is purported to be less 
sensitive to inhibition by opiates under these conditions (see above). 
Also, the alteration of the action potential plateau could result either 
from a decrease in the inward calcium current or an increase in an out-
ward potassium current. A change in the inward calcium current during 
presynaptic inhibition could be measured by impaling nerve terminals 
and voltage-clamping their membrane potential. Studies at an inverte-
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brate synapse come closest to achieving this ideal situation. In the 
abdominal ganglion of Aplysia, presynaptic inhibition of transmitter 
release from the identified cholinergic cell 110 occurs in response to 
stimulation of specific sensory fiber pathways. Transmitter release 
can be assayed by measuring the amplitude of synaptic potentials in 
follower cells of the 110 neuron. If the 110 neuron is voltage-clamped 
in the presence of tetrodotoxin, depolarizing pulses elicit graded 
transmitter release, suggesting at least partial control of the mem-
brane potential of the nerve terminals (Shapiro, Castellucci & Kandel, 
1980a). These step depolarizations of the soma, if carried out during 
pharmacological blockade of sodium channels (with tetrodotoxin) and 
potassium channels (with the combination of tetraethylammonium ions, 
4-aminopyridine and barium), elicit an inward current carried presum-
ably by calcium ions. During presynaptic inhibition caused by stimu-
lation of the sensory pathway, the transient inward calcium current· 
elicited by step depolarizations is decreased (Shapiro et al., 1980b). 
--
The mouse vas deferens preparation offers no convenient way of 
assessing the effect of opiates on the transient calcium c~rrents 
associated with transmitter release from the axon varicosities. There-
fore the amplitude of the e.j.p. was used as a measure of transmitter 
release and the ability of normorphine to depress this transmitter 
release was measured in the presence of different calcium ion concen-
trations. Halving or doubling the calcium ion concentration led to 
marked changes in the amount of transmitter released. However, the 
ability of normorphine to depress transmitter release \vas little 
changed by these manipulations. 
It may be argued that a different population of nerves was 
excited in the solutions with altered calcium ion concentration. 
Stimulus voltage was adjusted to compensate for the effect of 
altered calcium in order to obtain control e.j.ps of approximately 
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the same amplitude. However, if the stimulus voltage was not adjusted, 
normorphine was equally effective in low and in control calcium 
solutions, even though the pre-drug e.j.p. amplitudes differed. As 
already discussed, the potency of normorphine is independent of the 
initial amplitude of the e.j.p. 
If the· effects of normorphine on e.j.p. amplitude as summarized 
in Table 5 are reevaluated so that corrections for non-linear summation 
are made, then in some cells normorphine (1 ~M) is more effective in 
normal (2.54 m~) calcium than in low (1.27 mM) calcium. However, the 
depression of transmitter release by normorphine was not different in 
normal vs. low calcium if the results are averaged and a statistical 
comparison made (Table 7). 
4.62 Effect of calcium on e.j.p. amplitude- loci of action 
Could the alteration in e.j.p. amplitude by calcium ion be 
explained by actions at sites other than at the adrenergic varicosities 
which are releasing the transmitter? Calcium alters neuronal excita-
bility by shifting the voltage sensitivity of the system controlling 
membrane permeability to sodium and potassium; in high calcium, nerves 
are stabilized and in low calcium, nerves are more excitable 
(Frankenhaueser & Hodgkin, 1957). By reducing the number of nerves 
excited, elevated calcium might reduce e.j.p. amplitude, whereas in low 
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Table 7. Effect of normorphine (1 ].lM) on "transmitter release" 
(corrected for non-linear summation) in normal and low calcium: 
same cell. Results of Table 5 are corrected to account for non-
linear summation using the conversion formula of Table 6.* 
Depression of "transmitter release" 
by normorphine (1 ].lM) 
Cell I! Calcium (2.54 mM) Calcium (1.27 mM) 
7259-3 
8bl9-5 
8149-5 
10169-4 
10179-1 
-83% 
-76% 
-92% 
-88% 
-90% 
-86 + 
-89% 
-71% 
-69% 
-77% 
-90% 
2.9% -79 + 4.5% 
*There was no difference in the amount of depression of "transmitter 
release" by normorphine (1 ].lM) in normal calcium (2 .54 mM) vs. low 
calcium (1.27 mM) in the same cell (Student's t test, p>O.OS). 
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calcium more nerves would be excited by a given stimulus voltage, and 
e.j.p. amplitude would increase. But the relationship between e.j.p. 
amplitude and external calcium ion concentration in the present exper-
iments was in the opposite direction. 
Another possible locus of action of calcium ion in the mouse vas 
deferens is on the bioassay system used, the postsynaptic smooth muscle 
cells. The reaction of transmitter with the postsynaptic membrane may 
be changed. The membrane potential of smooth muscle cells is hyper-
polarized by excess calcium and depolarized by a decrease in calcium 
(Bulbring & Kuriyama, 1963). These changes occur without modification 
of the ionic content of the cell (see Casteels, 1970). Meaningful 
measurements of the resistance of the resting or active smooth muscle 
membrane as a function of the external calcium ion concentration cannot 
be made with a single microelectrode. Thus any effect on e.j.p. ampli-
tude of calcium-mediated alterations of membrane potential and resis-
tance cannot be determined. However, these effects are likely to be 
small because the manipulations of calcium ion concentration did not 
change the membrane potential by more than 5 mV in the present experi-
ments. The most likely site of action of calcium is thus the nerve 
terminal - a direct change in the stimulus-evoked transient inward 
calcium current that produces release of transmitter. Bennett & 
Florin (1975) previously reported that the amplitude of the e.j.p. in 
the mouse vas deferens is dependent on the extracellular calcium ion 
concentration. In their experiments the synaptic potential increased 
with about the second power of the extracellular calcium ion concen-
tration. 
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4.63 Interactions between calcium and opiates 
In the mouse vas deferens, both normorphine (Henderson & North, 
1976) and the calcium ion (Bennett & Florin, 1975) change the amplitude 
of the e.j.p. by acting at the same locus, the presynaptic nerve 
terminal. But the potency of normorphine is independent of the calcium 
ion concentration over a four-fold range (1.27-5.08 mM). These results 
allow two conclusions to be drawn. First, the affinity of normorphine 
for the opiate receptor and the efficacy of the resulting drug-receptor 
complex are ?Ulikely to be calcium-dependent. Second, considerable 
caution is warranted in the interpretation of studies of complex 
neuronal assemblies such as the central nervous system in vivo or a 
plexus of neurons in vitro, which claim to demonstrate antagonism of 
the effects of opiates by calcium. The interaction in these systems 
may be a functional antagonism which does not allow conclusions to be 
drawn concerning the mechanism of action of opiates. 
The action of opiates has also been tested in neuroblastoma x 
glioma hybrid cells exposed to differing concentrations of extra-
cellular calcium ion. Opiates and opioid peptides decrease cAMP levels 
in these cells even if calcium ion is omitted from the incubation 
medium. The inhibition by Leu5-enkephalin of PGE1-induced increases in 
cAMP levels is independent of the extracellular calcium ion concentra-
tion over a wide range (1 ~M- 20 mM) (Brandt, Buchen & Hamprecht, 
1980). 
How can the results in neuroblastoma x glioma hybrid cells 
(above) and the mouse vas deferens (present experiments) be reconciled 
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with the experimental evidence in favor of a major role for calcium ion 
in the actions of opiates? Opiates inhibit calcium uptake into brain 
synaptosomes (Guerrero-Munoz et al., 1978). In lysed synaptosomes, 
morphine inhibits only active (ATP-dependent) calcium uptake (Guerrero-
Munoz~ al., 1979). Furthermore, a high affinity binding site for 
calcium (~ = 0.85 ~M) located on synaptic membranes is selectively 
affected by opiates. The binding of calcium to this site is inhibited 
by preincubation of membranes in levorphanol (0.5-10 nM) and, further-
more, levorphanol can release calcium that has already been bound (Ross 
& Cardenas, .1977). Perhaps the high affinity, saturable calcium 
binding and the ATP-dependent calcium uptake are the same functional 
system. This system would be located on the inner surface of the 
synaptic membrane. It would be in some way coupled to extracellularly 
located opiate receptors such that binding of opiates to their recep-
tors would inhibit calcium uptake and binding. The function of such a 
system might be to maintain a low calcium ion concentration in a parti-
cular sub-compartment of the intracellular space. Opiates could act by 
increasing the calcium ion concentration of this compartment. Such an 
action could reduce the evoked release by transmitter in two ways. 
Firstly, the driving force for calcium entry during depolarization of 
the synaptic membrane could be reduced. Secondly, a calcium-dependent 
process could be activated which would, in turn, reduce transmitter 
release. One possible candidate is the calcium-dependent potassium 
conductance which has been demonstrated in several neuronal systems 
(see Thompson, 1977). An increased conductance to potassium ion would 
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hyperpolarize the terminal or pre-terminal membrane and possibly pre-
vent invasion of axon varicosities or by some other mechanism inhibit 
transmitter release (see below) . 
4.64 Mechanism of presynaptic inhibition by opiates: speculation 
Although the present findings provide evidence against an effect 
of calcium on the action of morphine, they do not directly refute a 
possible effect of morphine on calcium action in the nerve terminals. 
Thus it is possible that morphine is blocking the entry of calcium 
through its voltage-dependent channels, although if this blockade were 
competitive, it might be expected to be critically dependent on the 
external calcium ion concentration. Opiates could directly decrease 
the transient calcium current by completely closing some calcium 
channels, by decreasing the conductance of all channels, or by in-
creasing the voltage threshold at which they become activated. The 
calcium current could be indirectly depressed by decreasing the ampli-
tude or shortening the duration of the presynaptic action potential. 
At the squid giant synapse a decrease in the amplitude of the spike 
of the presynaptic terminal causes a decrease in the amount of trans-
mitter released from that terminal (Erulkar & Weight, 1977). An 
increase in an outward potassium current would shorten the action 
potential duration and decrease the voltage-dependent calcium current. 
Such a potassium current may or may not be calcium-dependent (Thompson, 
1977). Morphine could also leave unchanged the inward calcium current 
and instead decrease the amount of calcium available for interaction 
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with the transmitter release sites. This could be accomplished by 
increasing the affinity for calcium of another calcium-binding site in 
the nerve terminal. 
Another possible mechanism of action for presynaptic inhibitors 
of transmitter release is blockade of impulse propagation into the fine 
terminal ramifications of autonomic nerves. Such a mechanism has pre-
viously been considered for the inhibition of transmitter release by 
a-adrenergic agonists (Stjarne, 1978) as well as by opiates (Sastry, 
1978; North, 1979b). Blakeley & Cunnane (1979) provide electrophysio-
logical evidence that transmitter release from a given varicosity in 
the vas deferens is intermittent, which could reflect a lack of acti-
vation of each nerve fiber by every impulse. There is a large increase 
in the membrane surface area through which activating ionic currents 
must pass between the adrenergic axon and the nerve varicosity. Such a 
region would have a lower safety factor for impulse propagation, and 
hyperpolarization of the membrane would further reduce the safety 
factor (Van Essen, 1973). Hyperpolarization of neurons by opiates has 
been observed in the myenteric plexus of the guinea-pig ileum (see 
North, 1979b), in the locus coeruleus (Henderson, personal communica-
tion) and in the frog sympathetic ganglion (Wouters & van den Bercken, 
1979). Afferent fibers of the sural nerve terminate in the dorsal horn 
region of the spinal cord. The excitability of the terminal region of 
single Ao fibers of this nerve is decreased by morphine; hyperpolari-
zation of the terminals could produce this effect (Sastry, 1978). 
Although morphine does not alter the conduction of the action potential 
in non-terminal regions of the hypogastric or vagus nerves (Kosterlitz 
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& Wallis, 1964), the membrane of the terminal regions may have dif-
ferent properties. Possibly functional opiate receptors are found only 
in those regions. Hyperpolarization by morphine of the terminal 
portion of the preganglionic fibers of the frog sympathetic ganglion 
has been reported (Wouters & van den Bercken, 1980). 
Further experimentation with the mouse vas deferens and with 
other tissues that have opiate-sensitive transmitter release will hope-
fully produce more evidence to explain how opiates depress the nerve-
evoked release of transmitter substances. As the two predominant 
effects of opiates in the central nervous system are depression of 
the firing rate of neurons, and depression of transmitter release from 
nerve terminals, such information will aid in the understanding of how 
opiates produce their important pharmacological effects in man. 
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4.7 Proposals for future experiments 
4.71 Effects of prolonged exposure to opiates 
The present experiments have demonstrated that in vivo exposure 
of the mouse vas deferens to morphine results in the development of 
tolerance to the effect of normorphine on transmitter release, as 
assessed in vitro. It is of interest to find out if prolonged in vitro 
incubation of the vas deferens in morphine also leads to tolerance. If 
in vitro tolerance can be demonstrated, then factors which might enhance 
or block tolerance could be studied. Such factors, which are best 
studied in in vitro as opposed to in vivo experiments, include length 
of incubation time, incubation temperature, calcium ion concentration, 
and the presence of cyclic nucleotides and phosphodiesterase inhibitors 
or protein synthesis inhibitors. Incubation of vasa in the presence of 
D-Ala2-D-Leu5-enkephalin (DADL) would address the question of whether 
tolerance develops to actions of opiates mediated by 8 receptors, as 
well as to effects mediated by~ receptors. The extent of cross-
tolerance between ~ and 8 agonists could be quantitatively assessed in 
tissues incubated in vitro with either a ~ agonist (morphine) or a 8 · 
agonist (DADL). 
4.72 Cyclic nucleotides 
The results of testing cyclic nucleotides and phosphodiesterase 
inhibitors on e.j.ps in the mouse vas deferens raise many questions 
about the role of cAMP in transmitter release and about the pharmaco-
logy of these substances. More phosphodiesterase inhibitors should be 
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tested on the e.j.p. to see if potency in increasing e.j.p. amplitude 
is correlated with potency in inhibiting phosphodiesterase, and espe-
cially cAMP vs. cGMP specific phosphodiesterases. In order to elimin-
ate any problems of interpretation related to possible postsynaptic 
effects of these compounds, effects on transmitter release as assessed 
by overflow studies could be measured. 
It was observed that e.j.ps that had been increased in amplitude 
by IBMX did not facilitate when the stimulation frequency was increased 
(from 0.033 to 1Hz). Facilitation usually occurs at a stimulation 
frequency of· 1Hz. The effect of phosphodiesterase inhibitors on 
facilitation of transmitter release could be studied, and the role of 
calcium ion in the action of phosphodiesterase inhibitors also examined. 
The role of cyclic nucleotides in tolerance to opiates could be 
tested by co-incubating vasa deferentia in phosphodiesterase inhibitors 
or cyclic nucleotide analogs together with morphine in in vitro experi-
ments (see above). If such compounds do alter the development of 
tolerance, then the relative specificities of cAMP vs. cGMP selective 
phosphodiesterase inhibitors and cAMP vs. cGMP analogs could be inves-
tigated. 
4.73 Calcium ion 
Experiments which might further elucidate the possible role of 
the calcium ion in the inhibition of transmitter release by opiates in 
the mouse vas deferens include: 
(1) testing the effect of altered calcium ion concentration on e.j.p. 
amplitude in the presence of opiates; 
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(2) measuring the post-stimulus increase in spontaneous potentials, 
or the spontaneous potentials in the presence of elevated extra-
cellular potassium ion concentration, and determining if opiates 
change the frequency of these spontaneous events. A component of 
the spontaneous release under these latter two circumstances is 
reportedly dependent on extracellular calcium; the calcium depen-
dence of these phenomena would first have to be assessed by the 
use of calcium channel blockers such as cobalt ion; 
(3) loading liposomes with calcium ion and applying them to tissues 
bathed in zero calcium solution. If transmitter can be released 
by this method, the effectiveness of opiates on such release 
could be tested. An inhibition of liposome-induced transmitter 
release by opiates would imply an action of opiates on a release 
mechanism other than the depolarization-induced inward calcium 
current, because liposomes deposit the calcium ion directly into 
the intracellular compartment. 
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4.8 Summary 
1. Excitatory junction potentials were recorded by impalement of 
single smooth muscle cells of the mouse vas deferens in vitro. 
The amplitude of these potentials was used as a measure of the 
release of transmitter, which is most likely noradrenaline, from 
the varicosities in response to single pulse stimulation of the 
intramural nerves. 
2. E.j.ps were depressed by application of opiates and opioid 
peptides to the tissue. The Ec50 values were 560 nM for normor-
phine, 50 nM for D-Ala2-Met5-enkephalinamide (DAEA) and 500 pM 
for D-Ala2-D-Leu5-enkephalin (DADL). 
3. The potency of normorphine (100 nM, 300 nM and 1 ~M) was the same 
regardless of the control amplitude of the e.j.p. and of the 
stimulus strength used to evoke the e.j.p. 
4. In order to study the effect of prolonged exposure to morphine on 
neuro-effector. transmission in the vas deferens, two groups of 
mice were studied. One group was naive and the second group re-
ceived multiple injections of morphine sulphate (every 8 hours, 
up to 140 mg/kg) for 3 days. The vasa from morphine-pretreated 
mice were maintained in Krebs solution containing normorphine 
(300 nM). 
5. Prolonged exposure to morphine in vivo did not alter the resting 
membrane potential of single smooth muscle cells nor the contrac-
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tile response of the smooth muscle to exogenous noradrenaline. 
6. E.j.ps were depressed by normorphine in vasa from both groups of 
mice: the Ec 50 was 560 nM for the naive group and 6.6 ~M for the 
morphine-pretreated group. This shift to the right of the nor-
morphine dose-response curve could not be accounted for by the 
presence of normorphine (300 nM) in the Krebs solution of the 
morphine-pretreated mice. 
7. Adenosine (300 ~M and 1 mM) depressed the e.j.p. with equal 
potency in vasa from both groups of mice. 
8. Naloxone (300 nM) caused a marked (3.5 to 7-fold) increase in the 
e.j.p. amplitude of vasa from morphine-pretreated mice. The in 
vitro exposure of these vasa to normorphine could not account for 
this large effect. It is believed that the increase in response 
to naloxone of the nerve terminals may represent "dependence" on 
morphine in this tissue. 
9. These results indicate that prolonged exposure of a mouse vas 
deferens to morphine in vivo leads to the development of tolerance 
to the normal inhibitory effect of normorphine on transmitter 
release. This "presynaptic" tolerance is not associated with 
changes in resting membrane potential or sensitivity to trans-
mitter of the postsynaptic smooth muscle cells. 
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10. The involvement of adenosine 3' ,5 1 -cyclic monophosphoric acid 
(cAMP) in the action of opiates on transmitter release was tested 
by measuring the effectiveness of opiates in the presence of 
drugs which might elevate the cAMP concentrations in the nerve 
terminals: cAMP, dibutyryl cAMP (dbcAMP) and 1-methyl-3-iso-
butylxanthine (IBMX). 
11. Cyclic AMP and dbcAMP (1 mM) depressed the amplitude of the 
e.j.p., possibly by interacting with extracellular sites similar 
to those responsive to adenosine. 
12. The phosphodiesterase inhibitors IBMX (50 and 500 ~M) and 
SQ 20,006 (500 ~M) increased e.j.p. amplitude; this increase was 
much greater when the phosphodiesterase inhibitor was applied 
together with dbcAMP. It is believed that these increases in 
e.j.p. amplitude represent a presynaptic action on transmitter 
release, analogous to the effects of phosphodiesterase inhibitors 
at other sites of neuro-effector transmission. 
13. There was no change in the Ec50 for normorphine in the presence 
of cAMP (1 mM) or in the presence of the drug combination IBMX 
(50 ~M) and dbcAMP (500 ~M). Similarly, the depression of the 
e.j.p. by the opioid peptides DAEA and DADL was not affected by 
the combination IBMX (500 ~M) and dbcAMP (250 ~M). 
14. These findings provide evidence against the hypothesis that a 
reduction in cAMP levels in the nerve terminals is an essential 
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step in the inhibition by opiates and opioid peptides of trans-
mitter release. 
15. It has been proposed that the presynaptic action of opiates may 
result from a decrease in the depolarization-induced influx of 
calcium ions that precedes the release of transmitter from nerve 
terminals. The action of normorphine in the mouse vas deferens 
was therefore tested in tissues that were superfused with differ-
ent concentrations of calcium ion. 
16. Doubling or halving the calcium ion concentration from its usual 
value (2.54 mM) caused marked changes in the amplitude of the 
e.j.p. These alterations in the e.j.p. are likely to result from 
an effect of calcium on transmitter release. 
17. In vasa superfused with different concentrations of calcium ion, 
the stimulus strength was adjusted so that normorphine was tested 
on e.j.ps of approximately the same amplitude. Under these 
conditions the ability of normorphine to depress the e.j.p. was 
little changed in tissues superfused with calcium (1.27-5.08 mM). 
18. In cells in which the stimulus strength was not adjusted when the 
calcium ion concentration was changed, normorphine (1 ~M) was as 
effective in normal (2.54 mM) as in one-half (1.27 w~) calcium. 
19. Although these findings provide evidence against an effect of 
calcium on the action of normorphine, they do not directly refute 
a possible effect of normorphine on calcium action in the nerve 
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terminal. However, the affinity of normorphine for the opiate 
receptor and the efficacy of the resulting drug-receptor complex 
are unlikely to be calcium dependent. 
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